Devices, application systems and methods with localized heat flux zones for removing heat from subcutaneous lipid-rich cells

Information

  • Patent Grant
  • 10722395
  • Patent Number
    10,722,395
  • Date Filed
    Wednesday, January 25, 2012
    12 years ago
  • Date Issued
    Tuesday, July 28, 2020
    4 years ago
Abstract
Application systems, disposable interface assemblies and methods for cooling subcutaneous lipid-rich tissue. One embodiment of an application system includes a cooling unit, a cryoprotectant vessel, a contact member and an array of selectively addressable heating elements. The cryoprotectant vessel is configured to contain a fluidic cryoprotectant such that at least a portion of the cryoprotectant is cooled by the cooling unit to a desired base temperature. The contact member is attached to the cryoprotectant vessel and includes a backside in contact with the cryoprotectant and a front side opposite the backside. The contact member is configured to allow the cryoprotectant to flow from the backside to the front side. The array of selectively addressable heating elements is carried by the contact member.
Description
TECHNICAL FIELD

The present application relates generally to devices, application systems and methods for removing heat from subcutaneous lipid-rich cells. In particular, several embodiments are directed toward a device that provides independent control of the heat flux through a plurality of zones based on a desired heat flux profile.


BACKGROUND

Excess body fat, or adipose tissue, may be present in various locations of the body, including, for example, the thigh, buttocks, abdomen, knees, back, face, arms, chin, and other areas. Moreover, excess adipose tissue is thought to magnify the unattractive appearance of cellulite, which forms when subcutaneous fat protrudes into the dermis and creates dimples where the skin is attached to underlying structural fibrous strands. Cellulite and excessive amounts of adipose tissue are often considered to be unappealing. Moreover, significant health risks may be associated with higher amounts of excess body fat.


A variety of methods have been used to treat individuals having excess body fat and, in many instances, non-invasive removal of excess subcutaneous adipose tissue can eliminate unnecessary recovery time and discomfort associated with invasive procedures such as liposuction. Conventional non-invasive treatments for removing excess body fat typically include topical agents, weight-loss drugs, regular exercise, dieting or a combination of these treatments. One drawback of these treatments is that they may not be effective or even possible under certain circumstances. For example, when a person is physically injured or ill, regular exercise may not be an option. Similarly, weight-loss drugs or topical agents are not an option when they cause an allergic or negative reaction. Furthermore, fat loss in selective areas of a person's body often cannot be achieved using general or systemic weight-loss methods.


Other methods designed to reduce subcutaneous adipose tissue include laser-assisted liposuction and mesotherapy. Newer non-invasive methods include applying radiant energy to subcutaneous lipid-rich cells via, e.g., radio frequency and/or light energy, such as described in U.S. Patent Publication No. 2006/0036300 and U.S. Pat. No. 5,143,063, or via, e.g., high intensity focused ultrasound (HIFU) radiation such as described in U.S. Pat. Nos. 7,258,674 and 7,347,855. In contrast, methods and devices for non-invasively reducing subcutaneous adipose tissue by cooling are disclosed in U.S. Pat. No. 7,367,341 entitled “METHODS AND DEVICES FOR SELECTIVE DISRUPTION OF FATTY TISSUE BY CONTROLLED COOLING” to Anderson et al. and U.S. Patent Publication No. 2005/0251120 entitled “METHODS AND DEVICES FOR DETECTION AND CONTROL OF SELECTIVE DISRUPTION OF FATTY TISSUE BY CONTROLLED COOLING” to Anderson et al., the entire disclosures of which are incorporated herein by reference.





BRIEF DESCRIPTION OF THE DRAWINGS

In the drawings, identical reference numbers identify similar elements or acts. The sizes and relative positions of elements in the drawings are not necessarily drawn to scale. For example, the shapes of various elements and angles are not necessarily drawn to scale, and some of these elements are arbitrarily enlarged and positioned to improve drawing legibility. Further, the particular shapes of the elements as drawn are not necessarily intended to convey any information regarding the actual shape of the particular elements, and are generally selected for ease of recognition in the drawings.



FIG. 1 is an isometric view schematically illustrating a treatment system for treating subcutaneous lipid-rich regions of a subject in accordance with an embodiment of the technology.



FIG. 2A is a schematic cross-sectional view of an application system for cooling subcutaneous lipid-rich tissue in accordance with an embodiment of the technology.



FIG. 2B is a schematic bottom view of an interface assembly of an application system for cooling subcutaneous lipid-rich tissue in accordance with an embodiment of the technology.



FIG. 3 is a schematic cross-sectional view of an application system for cooling subcutaneous lipid-rich tissue in accordance with an embodiment of the technology.



FIG. 4 is a schematic cross-sectional view of an interface element of an interface assembly for cooling subcutaneous lipid-rich tissue in accordance with an embodiment of the technology.



FIGS. 5A and 5B are schematic views of an implementation of an application system for cooling subcutaneous lipid-rich tissue in accordance with an embodiment of the technology.



FIG. 6 is a schematic cross-sectional view of an application system for cooling subcutaneous lipid-rich tissue in accordance with an embodiment of the technology.



FIG. 7 is a schematic cross-sectional view of a treatment device with an application system for cooling subcutaneous lipid-rich tissue in accordance with an embodiment of the technology.





DETAILED DESCRIPTION

Overview


Several examples of devices, application systems and methods for independently controlling the heat flux through a plurality of cooling zones for cooling subcutaneous adipose tissue in accordance with the technology are described below. Although the following description provides many specific details of the following examples in a manner sufficient to enable a person skilled in the relevant art to practice, make and use them, several of the details and advantages described below may not be necessary to practice certain examples and methods of the technology. Additionally, the technology may include other examples and methods that are within the scope of the claims but are not described in detail.


Reference throughout this specification to “one example,” “an example,” “one embodiment” or “an embodiment” means that a particular feature, structure, or characteristic described in connection with the example is included in at least one example of the present technology. Thus, the occurrences of the phrases “in one example,” “in an example,” “one embodiment” or “an embodiment” in various places throughout this specification are not necessarily all referring to the same example. Furthermore, the particular features, structures, routines, steps or characteristics may be combined in any suitable manner in one or more examples of the technology. The headings provided herein are for convenience only and are not intended to limit or interpret the scope or meaning of the claimed technology.


One embodiment of an application system for cooling subcutaneous lipid-rich tissue comprises a cooling unit, a cryoprotectant vessel, a contact member and an array of selectably addressable heating elements. The cryoprotectant vessel is configured to contain a fluidic cryoprotectant such that at least a portion of the cryoprotectant is cooled by the cooling unit to a desired base temperature. The contact member is attached to the cryoprotectant vessel, and the contact member includes a backside in contact with the cryoprotectant and a front side opposite the backside. The contact member is configured to allow the cryoprotectant to flow from the backside to the front side, and the array of selectably addressable heating elements is carried by the contact member.


One embodiment of a method of operating an application system for cooling subcutaneous lipid-rich tissue includes cooling a cryoprotectant to a base temperature below 37° C. The method further includes passing the cyroprotectant through a flexible contact member of an interface element, and selectively heating at least one heating element of an array of heating elements carried by the flexible contact member to a temperature different than other heating elements of the array. As a result, the temperature of the cryoprotectant proximate to the heated heating element is raised to a contact temperature higher than the base temperature.


In a more detailed embodiment of an application system for cooling subcutaneous lipid-rich tissue, the cooling unit comprises a heat exchanger having a coolant chamber through which a coolant can flow. The cryoprotectant vessel comprises a back panel and a sidewall projecting from the back panel. The contact member is a flexible barrier attached to the sidewall of the cryoprotectant vessel to form a cryoprotectant chamber, and the flexible barrier and the cryoprotectant vessel together form a disposable interface element. The flexible barrier, for example, can be a porous membrane or other flexible panel with small holes. The interface assembly further comprises a connector that couples the cryoprotectant vessel to the cooling unit. The application system of this embodiment further comprises an array of temperature sensor sets carried by the flexible membrane, and each individual heating element is associated with a corresponding temperature sensor set. Additionally, the application system can optionally comprise a larger heating element spaced apart from the backside of the array of temperature sensor sets and a controller. The controller includes a computer-operable medium programmed to receive sensed temperatures from the temperature sensor sets and adjust the associated heating elements based on the sensed temperatures and a desired heating profile to thereby provide localized temperature differentials in the cryoprotectant corresponding to the desired heating profile.


General System Components



FIG. 1 and the following discussion provide a brief, general description of a suitable treatment system 10 in which aspects of the present technology can be implemented. Those skilled in the relevant art will appreciate that the present technology can be practiced with other systems and treatment protocols, including invasive, minimally invasive, other non-invasive cosmetic or medical treatment systems and/or combinations of one or more of the above for treating a subject 11. In general, the term “treatment system”, as used generally herein, refers to any of the above system categories of cosmetic or medical treatments as well as any treatment regimes or medical device usage.


The treatment system 10 is suitable for cooling the subcutaneous adipose tissue of a subject 11 in a manner that reduces the volume of the adipose tissue. “Subcutaneous tissue” can include tissue lying beneath the dermis and includes subcutaneous fat, or adipose tissue that may be composed primarily of lipid-rich cells, or adipocytes. When cooling subcutaneous tissues to a temperature lower than 37° C., subcutaneous lipid-rich cells can be affected selectively. In general, the epidermis and dermis of the subject 11 lack lipid-rich cells compared to the underlying lipid-rich cells forming the adipose tissue. Because non-lipid-rich cells usually can withstand colder temperatures better than lipid-rich cells, the subcutaneous lipid-rich cells can be affected selectively without affecting the non-lipid-rich cells in the dermis, epidermis and other surrounding tissue. In some embodiments, the treatment system 100 can apply cooling temperatures to the skin of the subject 11 in a range of about −20° C. to about 20° C. In other embodiments, the cooling temperatures can be from about −20° C. to about 10° C., approximately 0° C. to approximately 20° C., about −15° C. to about 5° C., approximately −5° C. to approximately 15° C., or about −10° C. to about 0° C.


Without being bound by theory, the selective effect of cooling on lipid-rich cells is believed to result in, for example, membrane disruption, cell shrinkage, disabling, destroying, removing, killing or other methods of lipid-rich cell alteration. Such alteration is believed to stem from one or more mechanisms acting alone or in combination. It is thought that such mechanism(s) trigger an apoptotic cascade, which is believed to be the dominant form of lipid-rich cell death by non-invasive cooling.


Apoptosis, also referred to as “programmed cell death”, is a genetically-induced death mechanism by which cells self-destruct without incurring damage to surrounding tissues. An ordered series of biochemical events induce cells to morphologically change. These changes include cellular blebbing, loss of cell membrane asymmetry and attachment, cell shrinkage, chromatin condensation and chromosomal DNA fragmentation. Injury via an external stimulus, such as cold exposure, is one mechanism that can induce cellular apoptosis in cells. Nagle, W. A., Soloff, B. L., Moss, A. J. Jr., Henle, K. J. “Cultured Chinese Hamster Cells Undergo Apoptosis After Exposure to Cold but Nonfreezing Temperatures” Cryobiology 27, 439-451 (1990).


One aspect of apoptosis, in contrast to cellular necrosis (a traumatic form of cell death causing local inflammation), is that apoptotic cells express and display phagocytic markers on the surface of the cell membrane, thus marking the cells for phagocytosis by macrophages. As a result, phagocytes can engulf and remove the dying cells (e.g., the lipid-rich cells) without eliciting an immune response. Temperatures that elicit these apoptotic events in lipid-rich cells may contribute to long-lasting and/or permanent reduction and reshaping of subcutaneous adipose tissue.


One mechanism of apoptotic lipid-rich cell death by cooling is believed to involve localized crystallization of lipids within the adipocytes at temperatures that do not induce crystallization in non-lipid-rich cells. The crystallized lipids selectively may injure these cells, inducing apoptosis (and may also induce necrotic death if the crystallized lipids damage or rupture the bi-lipid membrane of the adipocyte). Another mechanism of injury involves the lipid phase transition of those lipids within the cell's bi-lipid membrane, which results in membrane disruption, thereby inducing apoptosis. This mechanism is well-documented for many cell types and may be active when adipocytes, or lipid-rich cells, are cooled. Mazur, P., “Cryobiology: the Freezing of Biological Systems” Science, 68: 939-949 (1970); Quinn, P. J., “A Lipid Phase Separation Model of Low Temperature Damage to Biological Membranes” Cryobiology, 22: 128-147 (1985); Rubinsky, B., “Principles of Low Temperature Preservation” Heart Failure Reviews, 8, 277-284 (2003). Other yet-to-be understood apoptotic mechanisms may exist, based on the relative sensitivity of lipid-rich cells to cooling compared to non-lipid rich cells.


In addition to the apoptotic mechanisms involved in lipid-rich cell death, local cold exposure also is believed to induce lipolysis (i.e., fat metabolism) of lipid-rich cells and has been shown to enhance existing lipolysis which serves to further increase the reduction in subcutaneous lipid-rich cells. Vallerand, A. L., Zamecnik. J., Jones, P. J. H., Jacobs, I. “Cold Stress Increases Lipolysis, FFA Ra and TG/FFA Cycling in Humans” Aviation, Space and Environmental Medicine 70, 42-50 (1999).


In various embodiments, the treatment system 10 includes a controller, a computing device, a data acquisition device, a chiller, and one or more treatment devices. These components can be implemented in various embodiments to apply selected treatment profiles to a subject 11 (e.g., a human or animal) for reducing adipose tissue.



FIG. 1 is a perspective view illustrating one example of a treatment system 10 for non-invasively removing heat from subcutaneous lipid-rich target areas of the subject 11, such as an abdominal area 12 or another suitable area. The system 10 may include a treatment device 14 that engages the target area of the subject 11 and a treatment unit 16 that operate together to cool or otherwise remove heat from the subcutaneous lipid-rich cells of the subject 11. The treatment devices 14 can be part of an application system, and the treatment device 14 can have various, configurations, shapes and sizes suitable for different body parts such that heat can be removed from any subcutaneous lipid-rich target area of the subject 11. For example, the treatment devices 14 may be designed to treat target areas of the patient's body, such as chin, cheeks, arms, pectoral areas, thighs, calves, buttocks, back, abdomen, “love handles” and so forth. The treatment devices 14 can have a cooling unit 15 that cools a selected area of the subject 11. As explained in more detail below, the system 10 can also include a disposable protective device and a cryoprotect for cooling the lipid-rich adipose tissue.


In the embodiment illustrated in FIG. 1, the treatment device 14 may provide mechanical energy to create a vibratory, massage and/or pulsatile effect in addition to cooling subcutaneous adipose tissue, such as the devices described in U.S. Pat. No. 7,367,341 and commonly assigned U.S. Patent Publication No. 2008/0287839. The treatment device 14, for example, may include one or more actuators that generate a transitory force which is transmitted to the subject. Suitable actuators include motors with eccentric weights, hydraulic motors, electric motors, pneumatic motors, solenoids, other mechanical motors, piezoelectric shakers and other devices that provide vibratory energy to the treatment site. A single treatment device 14 may have a plurality of different types of actuators in any desired combination. For example, the treatment device 14 may have an eccentric weight actuator (not shown) and a pneumatic motor (not shown) such that different effects may be provided with the same treatment device 14. This would provide a number of options for differential treatments of lipid rich cells within a single target area or among multiple target areas of subject 11.


The cooling unit 15 can be a component of a cooling unit integrated with the treatment device 14, and the cooling unit 15 may include one or more Peltier-type thermoelectric elements, such as a plurality of individually controlled thermal segments that create a custom spatial cooling profile and/or a time-varying cooling profile. Each custom treatment profile can include one or more segments, and each segment can include a specified duration, a target temperature, and control parameters for features such as vibration, massage, vacuum and other treatment modes. Cooling devices having multiple individually controlled heat exchanging units are described, e.g., in commonly assigned U.S. Patent Publication No. 2008/0077211.


The treatment unit 16 may be a refrigeration unit, a cooling tower, a thermoelectric chiller or cooler or any other device or cooling unit capable of removing heat from a coolant in addition to or in lieu of the cooling unit 15 at the treatment device. The treatment unit 16 can be operatively coupled to the treatment device 14 by supply and return fluid lines 18a and 18b that circulate chilled fluid (e.g., a coolant) through the treatment device 14. Alternatively, the treatment unit 16 can circulate warm fluid to the treatment device 14 during periods of warming. Examples of the circulating coolant include water, glycol, synthetic heat transfer fluid, oil, a refrigerant, a cryoprotectant and/or any other suitable heat-conducting fluid. The fluid lines 18a and 18b may be hoses or other conduits constructed from polyethylene, polyvinyl chloride, polyurethane and/or other materials that can accommodate the particular circulating coolant. Furthermore, one skilled in the art will recognize that there are a number of other cooling technologies that could be used such that the cooling units or coolers of the treatment unit 16 or the treatment device 14 need not be limited to those described herein.


The system 10 may further include a power supply 20 and a processing unit 24 operatively coupled to the treatment device 14, the cooling unit 15 and/or the treatment unit 16. In one example, the power supply 20 provides a direct current voltage to a thermoelectric element of the cooling unit 15 to adjust the heat flux over a relatively large area. The processing unit 24 may monitor process parameters via sensors (not shown) placed proximate to the treatment device 14 through power line 26 to, among other things, adjust the heat removal rate based on the process parameters. The processing unit 24 may further monitor process parameters to adjust the cooling unit 15 or other components based on the process parameters.


The processing unit 24 may be in direct electrical communication with treatment device 14 through the electrical line 22 as shown in FIG. 1; alternatively, processing unit 24 may be connected to treatment device via a wireless or an optical communication link. For example, the processing unit 24 may be in electrical communication with a control panel of the treatment device 14, the cooling unit 15 and/or an interface assembly. The processing unit 24 may be any processor, programmable logic controller, distributed control system and so on. Although the power line 26 and the electrical line 22 are shown in FIG. 1 without any support structure, these lines and other lines including, but not limited to the fluid lines 18a and 18b, may be bundled into or otherwise accompanied by a conduit or the like to protect the lines, enhance user safety and ergonomic comfort, inhibit unwanted motion that could adversely impact the heat transfer rate, provide electrical and thermal insulation and provide an aesthetic appearance to the system 10. Examples of such a conduit include a flexible polymeric fabric, a composite sheath, an adjustable arm, etc. Such a conduit (not shown) may be designed (via adjustable joints, etc.) to “set” the conduit in place for the treatment of the subject 11.


The system 10 can also include an input device 28 and an output device 30 operatively coupled to the processing unit 24. The input device 28 may be a keyboard (shown in FIG. 1), a mouse, a touch screen, a push button, a switch, a potentiometer, any combination thereof and any other device or devices suitable for accepting user input. The output device 30 may include a display or touch screen, a printer, a medium reader, an audio device, a visual device, any combination thereof and any other device or devices suitable for providing user feedback. In the embodiment of FIG. 1, the input device 28 and the output device 30 may be combined in a single unit such as a touch screen. The control panel 14b may include visual indicator devices or controls (lights, numerical displays, etc.) and/or audio indicator devices or controls. The control panel of the treatment device 14 may be a separate component from the input device and/or output device as shown in FIG. 3, or the control panel may be (a) integrated with one or more of the input and output devices 28 and 30, (b) partially integrated with one or more of the input and output devices 28 and 30, (c) at another location, and so on. In this example, the processing unit 24, the power supply 20, the treatment unit 16, the input device 28 and the output device 30 are carried by a rack or cart 34 with wheels 36 for portability. In alternative examples, the processing unit 24 may be contained in, attached to, or integrated with the treatment device 14, the cooling unit 15 and/or an interface assembly. In yet another example, the various components may be fixedly installed at a treatment site. Further details with respect to selected versions of the components and/or operation of the treatment device 14, cooling unit 15 and other components may be found in commonly-assigned U.S. Patent Publication No. 2008/0287839.


Without being bound by theory, it is believed that effective conductive cooling from the treatment device 14 depends on a number of factors. Examples of factors that impact heat removal or extraction from the skin and related tissue include, for example, the surface area of the treatment unit, the temperature of the interface member, the mechanical energy delivered to the tissue, the distribution of cryoprotectant and the extent of non-uniformities in the contact between the interface member and the skin. More specifically, upon receiving input to start a treatment protocol, the processing unit 24 can cause the treatment device 14 to cycle through each segment of a prescribed treatment plan. In so doing, the treatment device 14 applies power to one or more cooling segments, such as thermoelectric coolers (e.g., TEC “zones”), to begin a cooling cycle and, for example, activate features or modes such as vibration, massage, vacuum, etc. Using temperature or heat flux sensors, the processing unit 24 determines whether the temperature and/or heat flux at one or more areas of the actuator are sufficiently close to a target temperature or target heat flux. It will be appreciated that while a region of the body (e.g., adipose tissue) has been cooled or heated to the target temperature or by a target heat flux, in actuality that region of the body may be close but not equal to the target temperature, e.g., because of the body's natural heating and cooling variations. Thus, although the system may attempt to heat or cool to the target temperature or by a target heat flux, a sensor may measure a sufficiently close temperature. If the target temperature has not been reached, power can be increased or decreased to change heat flux, as needed, to maintain the target temperature or “set-point.” When the prescribed segment duration expires, the processing unit 24 may apply the temperature and duration indicated in the next treatment profile segment. In some embodiments, temperature can be controlled using a variable other than, or in addition to, power.


A cryoprotectant is used with the treatment device 14. Among other advantages, a cryoprotectant can assist in preventing freezing of non lipid-rich tissue (e.g., dermal tissue) during treatment. Suitable cryoprotectants and processes for implementing cryoprotectants are described in commonly-assigned U.S. Patent Publication No. 2007/0255362 and U.S. patent application Ser. No. 13/011,640 filed on Jan. 21, 2011, which are hereby incorporated by reference. As used herein, “cryoprotectant” means a flowable compound that prolongs the time to freeze non lipid-rich tissue (e.g., dermal tissue) compared to an absence of the compound.


In one example of operating the system 10, the treatment device 14 is drawn against the skin of the subject 11 to achieve efficient treatment. The subject 11 generally has a body temperature of about 37° C., which is maintained at a relatively constant level by circulation of blood. As a result, blood flow through the skin and subcutaneous layer of the region to be treated acts as a heat source that counteracts the cooling of the subdermal fat. Cooling the tissue of interest accordingly requires not only removing the heat from the target tissue but also from the blood circulating through this tissue. The efficiency of cooling the tissue can be enhanced by temporarily reducing or eliminating blood flow through the treatment region using a vacuum or other technique. Applying a vacuum may also pull skin and underlying adipose tissue away from the body which can assist in cooling underlying tissue by increasing the distance between the subcutaneous fat and the relatively well-perfused muscle tissue and by allowing the underlying adipose tissue simultaneously to be cooled from two sides.


By cooling the subcutaneous tissue to a temperature lower than 37° C., subcutaneous lipid-rich cells may be damaged selectively. In general, the epidermis and dermis of the subject 11 have lower amounts of fatty acids compared to the underlying lipid-rich cells forming the subcutaneous tissues. Because non-lipid-rich cells usually can withstand colder temperatures better than lipid-rich cells, the subcutaneous lipid-rich cells can be injured selectively while maintaining the non-lipid-rich cells in the dermis and epidermis. The presence of a cryoprotectant at and/or on the dermal tissue enhances the selectivity such that the dermal tissue can withstand even colder temperatures which induce cell death in more lipid-rich tissue. For example, the temperature range may be from about −10° C. to about 0° C.


Several embodiments of the system 10 may damage, injure, disrupt or otherwise reduce subcutaneous lipid-rich cells generally without collateral damage to non-lipid-rich cells in the treatment target area. In general, it is believed that lipid-rich cells can be affected selectively (e.g., damaged, injured or disrupted) by exposing such cells to low temperatures that do not adversely affect non-lipid-rich cells to the same extent or in the same manner. As a result, lipid-rich cells, such as subcutaneous adipose tissue, can be damaged while other cells in the same region are generally not damaged even though the non-lipid-rich cells at the surface are subject to even lower temperatures. The mechanical energy provided by the applicator may further enhance the effect on lipid-rich cells by mechanically disrupting the affected lipid-rich cells.



FIG. 2A is a schematic cross-sectional view of an application system 100 for cooling subcutaneous lipid-rich tissue. The application system 100, for example, may include a treatment device and a cooling unit integrated with the treatment device and/or with the treatment unit. In this embodiment, the application system 100 is a treatment device configured to contact the target area. The application system 100 can include a cooling unit 110 and an interface assembly 120 operably coupled to the cooling unit 110. The cooling unit 110, for example, may be similar to the cooling unit 15 of the treatment device 14 described above with reference to FIG. 1. The embodiment of the cooling unit 110 shown on FIG. 2A can include a plate 112 that has a high thermal conductivity, one or more Thermoelectric Elements (TEEs) 114 and a coolant chamber 116. As explained above with reference to FIG. 1, a coolant can recirculate through the coolant chamber 116 via inlet and outlet lines 118a and 118b, respectively, and the TEEs 114 can selectively heat and/or cool relative to the temperature of the coolant in the coolant chamber 116 to control the temperature over relatively large areas of the cooling plate 112. Other embodiments of the cooling unit 110 do not include the TEEs 114 such that the coolant chamber 116 extends to the cold plate 112. In either case the cooling unit 110 provides a heat sink that cools the interface assembly 120.


The interface assembly 120 further controls the heat flux through a plurality of smaller zones and delivers a cryoprotectant to the target area. In one embodiment, the interface assembly 120 includes a cryoprotectant container 130 having a cavity 132 that contains a cryoprotectant 140 and an interface element 150 through which the cryoprotectant 140 can flow. The cryoprotectant container 130 can be a rigid or flexible vessel having a back panel 134 facing the cooling unit 110 and a sidewall 136 projecting from the back panel 134. The interface element 150 can be attached to the sidewall 136 to enclose the cavity 132. The interface element 150 can include a contact member 152 having a backside 153a in contact with the cryoprotectant 140 and a front side 153b configured to contact the epidermis of the subject. The contact member 152 can be a flexible barrier (e.g., membrane) such as a porous sheet of a polymeric material or a foil with small holes, a mesh, fabric or other suitable material through which the cryoprotectant 140 can flow from the backside 153a to the front side 153b. In other embodiments, the contact member 152 can be a substantially rigid barrier that is thermally conductive and configured to allow the cryoprotectant 140 to pass from the front side 153b to the backside 153a. A rigid contact member, for example, can be a plate with holes or a panel made from a porous metal material. Suitable materials for a rigid contact member 152 include aluminum, titanium, stainless steel, or other thermally conductive materials.


The interface element 150 of the application system 100 further includes an array of heating elements 154 carried by the contact member 152. The individual heating elements 154 can be arranged in a grid or other type of pattern, and each heating element 154 is independently controlled relative to the other heating elements to provide control of the heat flux through smaller, discrete zones at the interface between the target area and the interface element 150. The heating elements 154, for example, can be micro-heaters electrically coupled to a power source via a cable 155 such that the controller can selectably address individual heating elements 154. The interface element 150 can further include a plurality of temperature sensors 156 carried by the contact member 152. The temperature sensors 156 may be arranged in an array such that one or more temperature sensors can measure the heat flux through the heat flux zones associated with one or more individual heating elements 154. The temperature sensors 156 can be electrically coupled to a control unit via a cable 157 in a manner similar to the heating elements 154.



FIG. 2B is a schematic bottom view of the interface element 150. Referring to FIGS. 2A and 2B together, the heating elements 154 can be arranged in a grid having C1-Cn columns and R1-Rn rows. Each individual heating element 154 can define a heat flux zone Z through which the heat flux can be selectively controlled relative to other areas of the interface element 150 (see, e.g., heat flux zones Z1, Z2 and Z3). In other embodiments, a plurality of heating elements 154 can be grouped together into a set that defines a heat flux zone (see, e.g., heat flux zone Z4). In other embodiments, the heating elements 154 can be arranged in different configurations. The temperature sensors 156 can also be arranged in the same grid as the heating elements 154. For example, each column-row address can have one or more temperature sensors 156 to measure the temperature and/or heat flux associated with each individual heating element 154 or heat flux zone.


The cable 155 (FIG. 2A) can include a plurality of individual wires that electrically couple corresponding individual heating elements 154 to a multi-channel power source. The cable 157 (FIG. 2A) can similarly include individual wires that electrically couple the temperature sensors 156 to an analog-to-digital converter, which is then coupled to a controller. In operation, the controller can operate the power source to selectively address the independent heating elements 154 based upon the column and row to provide a desired cooling profile in the subcutaneous lipid-rich tissue.


In operation, a target site of the subject is registered relative to the grid of heating elements of the interface element 150. The target site can have a single heat flux zone, or the target site can be divided into a number of different areas in which each area is associated with a corresponding heat flux zone. In either situation, a practitioner inputs the extent of desired cooling for the heat flux zones or this information can be provided to the controller by a predetermined control algorithm. The interface element 150 is positioned at the target site of the subject. In many applications, the interface element 150 and the epidermis of the target site are coapted under pressure provided by a vacuum, belt or other mechanism that forces the skin of the subject against the interface element 150. The cryoprotectant 140 in the cryoprotectant container 130 flows through the interface element 150 and contacts the skin of the subject, and a coolant is recirculated through the coolant chamber 116 of the cooling unit 110 to globally cool the back panel 134 of the cryoprotectant container 130.


The temperature at the back panel 134 can be optionally controlled regionally using TEEs 114. The cooling provided by the cooling unit 110 reduces the temperature of the cryoprotectant 140 in the cryoprotectant container 130 to a base temperature. While the interface element 150 contacts the target site, a controller selectively activates the heating elements 154 to control the heat flux through the heat flux zones across the target site. The temperature and/or heat flux at the individual heat flux zones across the target site can be monitored via the temperature sensors 156 to provide closed loop control of the heat flux according to the predetermined algorithm. Suitable algorithms for defining and controlling the heat flux are disclosed in U.S. Patent Publication No. 2010/0152824 (U.S. patent application Ser. No. 12/337,544), which is herby incorporated by reference.


Several embodiments of the application assembly 100 enhance the control of the heat flux across different regions of the target area. This can be useful because different subjects may have different deposits of lipid-rich tissue within a target area, or the subject may have particularly sensitive dermal tissue at particular regions of the target area. Moreover, the enhanced control of the heat flux through the individual heat flux zones enables more accurate control of the cooling profile within the lipid-rich tissue.



FIG. 3 is a schematic illustration of an application system 200 for cooling subcutaneous lipid-rich tissue in accordance with another embodiment of the technology. Like reference numbers refer to similar components in FIGS. 2A-3. The embodiment of the application system 200 shown in FIG. 3 includes a cooling unit 210 and treatment device having an interface assembly 220 located remotely from the cooling unit 210. For example, the cooling unit 210 can be a cooler or chiller in the treatment unit 16 located in the rack or cart 34 shown in FIG. 1. In this particular embodiment, the cryoprotectant vessel 130 further includes outlet/inlet ports 137a and 137b, respectively, and the application system 200 further includes recirculation lines 212a and 212b extending between the cooling unit 210 and the interface assembly 220. In operation, the cooling unit 210 cools and recirculates the cryoprotectant 140 through the recirculation lines 212a-b and the cavity 132 of the cryoprotectant container 130. The cryoprotectant 140 flows through the contact member 152, and the heating elements 154 control the heat flux through the heat flux zones as described above with reference to FIGS. 2A and 2B. The application system 200 of this embodiment accordingly cools the cryoprotectant remotely from the interface assembly 220. As such, the cooling unit 220 and recirculation lines 212a-b can be flushed or cleaned between treating different subjects, and/or the cryoprotectant 140 can include a germicide.



FIG. 4 is a schematic cross-sectional view of another embodiment of an interface element 400 for use in the application assembly 100 for cooling subcutaneous lipid-rich tissue. In this embodiment, the interface element 400 includes a flexible barrier 410 having a backside 411a, a front side 411b opposite the backside 411a and a plurality of channels 412 or other structure through which the cryoprotectant can pass from the backside 411a to the front side 411b (e.g., a porous structure). The interface element 400 further includes a thermal gradient layer 414 having a known thickness, thermal conductivity and heat capacity. The thermal gradient layer 414 has a plurality of striations 416 or other types of discontinuities that divide the thermal gradient layer 414 into a plurality of heat flux units 418. The interface element 400 further includes a set of temperature sensors having a dorsal temperature sensor 420 and a ventral temperature sensor 422 associated with each heat flux unit 418. The dorsal temperature sensors 420 indicate the temperature of the thermal gradient layer 414 toward the backside 411a of the barrier 410, and the ventral temperature sensors 422 indicate the temperature of the thermal gradient layer 414 toward the skin of the subject. The heat flux through each heat flux unit 418 can be determined based upon the difference between the dorsal and ventral temperature sensors 420 and 422 in combination with the known thickness, thermal conductivity and heat capacity of the thermal gradient layer 414.


The embodiment of the interface element 400 shown in FIG. 4 further includes a plurality of heating elements 454. More specifically, the interface element 400 can include one or more heating element 454 associated with individual heat flux units 418. The interface element 400 can optionally include a backside heating element 456 at the backside 411a of the barrier 410. The backside heating element 456 can globally heat the cryoprotectant at the backside 411a to provide a desired known temperature uniformly across the backside 411a. In operation, the cooling unit (not shown in FIG. 4) is set to a base temperature and the backside heating element 456 is adjusted to provide the desired backside temperature of the cryoprotectant. This enables quick and accurate adjustment of the set point for the cryoprotectant entering the interface element 400. The heating elements 454 are then controlled to provide the desired heat flux through the individual heat flux units 418. As described above, a heat flux zone can be defined by a single heat flux unit 418, or a set of heat flux units 418 can define a heat flux zone.



FIGS. 5A and 5B illustrate another implementation of application assemblies for cooling subcutaneous lipid-rich tissue in accordance with the technology. In this embodiment, one or more markers 510 are placed on the skin 520 of the subject 11 such that the markers 510 define the perimeter of the target area. The interface assembly 120 is positioned so that a number of the heating elements 154 are superimposed over the region defined by the markers 510. The heating elements 154 are then controlled based upon the outline of the target area defined by the markers 510 and the desired heat flux through the various heat flux zones 530. In the illustrated embodiment, for example, the heat flux through the heat flux zones 530 associated with columns C2 and C3 can be greater than that through the corresponding heat flux zones 530 associated with columns C1 and C4. This can be achieved by providing more heat to the heating elements in columns C1 and C4 compared to those in columns C2 and C3 and/or the smaller surface areas defined by the markers 510 in columns C1 and C4. Referring to FIG. 5B, this provides a controlled treatment profile P that extends through the skin 520 and into the lipid-rich tissue 522 for reducing the volume of the lipid-rich tissue as described above.


The markers 510 can be conductive members or dielectric templates. In one example, the markers 510 are a conductive ink or magnetic ink that is deposited on the skin 520 of the patient around the perimeter of the treatment area. The heating elements 154 can include sensors that detect the presence of the inks, and the controller can then selectively operate the heating elements based on the outline of the markers 510. In another example, the markers 510 are defined by a dielectric template that has an opening in the shape of the treatment area. The heating elements 154 can be operated to focus the heat flux through the opening of the template. For example, the heating elements 154 can sense the heat flux through the corresponding heat flux zones, and the controller can determine the shape of the opening based on a greater heat flux through the opening compared to areas covered by the dielectric material.



FIG. 6 is a schematic cross-sectional view of another embodiment of the application system. In this embodiment, the interface assembly 120 further includes a connector 170 that couples the cryoprotectant vessel 130 to the cooling unit 110. The connector 170 can comprise a sheath or pocket in which cooling unit 110 is received to treat a subject. After performing the treatment, the interface assembly 120 can be removed and disposed appropriately. The cooling unit 110 can then be inserted into a new, sterile interface assembly for treating the next subject.



FIG. 7 is a schematic cross-sectional view of an application system 700 for cooling lipid-rich tissue in accordance with another embodiment of the technology. The treatment device 700 includes a vacuum cup 702 having a vacuum port 704, a first cooling unit 710a on one side of the cup 702, and a second cooling unit 710b on an opposing side of the cup 702. Each of the first and second cooling units 710a and 710b can be similar to the cooling unit 110 described above with reference to FIGS. 2A and 2B. As such, each of the cooling units 710a-b can include a cold plate 712 and a coolant chamber 716. The cooling units 710a-b can be fixed to the vacuum cup 702.


In this embodiment, the treatment device 700 also includes a first interface assembly 120a and a second interface assembly 120b within the vacuum cup 702. More specifically, the first interface assembly 120a is adjacent the first cooling unit 710a and the second interface assembly 120b is adjacent the second cooling unit 710b. The first and second interface assemblies 120a-b can further include connectors 170 in the form of tabs or other mechanisms that can be secured by clasps or clamps 171 to releasably attach the first and second interface assemblies 120a-b to the vacuum cup 702. The first and second interface assemblies 120a-b can also be connected to each other by a flexible intermediate portion 180. The intermediate portion 180 can include a vacuum port 182 aligned with the vacuum port 704 of the vacuum cup 702, or the intermediate portion 180 can have a porous through which air can flow. In operation, the rim of the vacuum cup is placed against the skin of a subject and a vacuum is drawn within the cup. The vacuum pulls the tissue of the subject into the cup 702 and coapts the target area with the interface elements 150 of the corresponding first and second interface assemblies 120a-b. One suitable vacuum cup 702 with cooling units is described in U.S. Provisional Patent Application Ser. No. 61/174,407, filed on Apr. 30, 2009, and incorporative by reference above.


From the foregoing, it will be appreciated that specific embodiments of the invention have been described herein for purposes of illustration, but that various modifications may be made without deviating from the spirit and scope of the invention. The application systems, interface assemblies and methods may be combined in further embodiments. For example, the interface element 400 shown and described with reference to FIG. 4 can be used in any of the interface assemblies 120, 120a-b or 200 described above with reference to FIGS. 2A-3 and 5A-7. In addition, while advantages associated with certain embodiments have been described and the context of those embodiments, other embodiments may also exhibit such advantages. Not all embodiments need necessarily exhibit such advantages to fall within the scope of the present disclosure. Accordingly, the invention is not limited except as by the appended claims.

Claims
  • 1. An application system for cooling subcutaneous lipid-rich tissue, comprising: a cooling unit; a cryoprotectant vessel configured to contain a cryoprotectant such that at least a portion of the cryoprotectant is cooled by the cooling unit to a desired cold temperature; a contact member configured to be attached to the cryoprotectant vessel, the contact member including a backside configured to contact the cryoprotectant and a front side opposite the backside and a thermal gradient layer having one or more physical discontinuities configured to define one or more units of the thermal gradient layer, wherein each unit is associated with one or more of a plurality of selectably addressable heating elements; an array of the plurality of selectably addressable heating elements carried by the contact member, and wherein the contact member is configured to allow the cryoprotectant to flow from the backside to the front side; and a controller with a stored profile and being programmed to cause the application system to cool the subcutaneous lipid-rich tissue, and command one or more heating elements of the array of selectably addressable heating elements to warm the subcutaneous lipid-rich tissue, which has been cooled by the application system, based on the stored profile while the application system cools the subcutaneous lipid-rich tissue to disrupt subcutaneous lipid-rich cells, wherein the stored profile includes a target heat flux profile, a target temperature profile, or a combination thereof.
  • 2. The application system of claim 1, wherein the cooling unit comprises a heat exchanger having a coolant chamber through which a coolant can flow;wherein the cryoprotectant vessel comprises a backpanel and a sidewall projecting from the backpanel, the contact member is a flexible barrier attached to the sidewall of the cryoprotectant vessel to form a cryoprotectant chamber, the flexible barrier and the cryoprotectant vessel together form an interface assembly, and the interface assembly further comprises a connector coupling the cryoprotectant vessel to the cooling unit;the application system further comprising an array of temperature sensor sets carried by the flexible barrier, wherein individual heating elements of the array of selectably addressable heating elements are associated with corresponding temperature sensor set of the array of temperature sensor sets;the application system further comprising an additional heating element positioned to heat the cryoprotectant contained in the cryoprotectant vessel, the additional heating element being spaced apart from the array of temperature sensor sets; andthe application system further comprising a controller including a computer-operable medium programmed to receive sensed temperatures from the temperature sensor sets and adjust the associated individual heating elements of the array of selectably addressable heating elements based on the sensed temperatures and a desired heating profile, thereby providing localized temperature differentials in the cryoprotectant corresponding to the desired heating profile.
  • 3. The application system of claim 1, wherein the cooling unit comprises a cold plate and a heat exchanger having a coolant chamber through which a coolant can flow, and wherein the heat exchanger is in thermal communication with the cold plate.
  • 4. The application system of claim 3, wherein the cooling unit further comprises at least one thermoelectric element between the cold plate and the heat exchanger.
  • 5. The application system of claim 1, wherein the contact member is a flexible barrier attached to the cryoprotectant vessel such that the flexible barrier and the cryoprotectant vessel together form an interface element.
  • 6. The application system of claim 5, wherein the interface element further comprises a connector coupling the cryoprotectant vessel to the cooling unit.
  • 7. The application system of claim 6, wherein the connector comprises a sheath associated with the cryoprotectant vessel, and the cooling unit is received within the sheath.
  • 8. The application system of claim 7 wherein the sheath and the cryoprotectant vessel are integrally formed together such that the sheath extends from the cryoprotectant vessel.
  • 9. The application system of claim 6 wherein the connector comprises a tab extending from the cryoprotectant vessel, and wherein the application system includes a clasp configured to releasably hold the tab.
  • 10. The application system of claim 1, wherein the cryoprotectant vessel comprises a backpanel facing the cooling unit and a sidewall projecting from the backpanel, and wherein the contact member is a flexible barrier attached to the sidewall of the cryoprotectant vessel to form a cryoprotectant chamber.
  • 11. The application system of claim 10, wherein the interface assembly further comprises a pad containing a cryoprotectant gel in the cryoprotectant chamber.
  • 12. The application system of claim 10, wherein the cryoprotectant vessel further comprises an inlet into the cryoprotectant chamber and an outlet from the cryoprotectant chamber such that cryoprotectant can flow through the cryoprotectant chamber.
  • 13. The application system of claim 1, wherein the cryoprotectant vessel further comprises an inlet and an outlet configured to direct a flow of the cryoprotectant through the cryoprotectant vessel.
  • 14. The application system of claim 13, wherein: the cryoprotectant vessel comprises a backpanel, a sidewall projecting from the backpanel, an inlet and an outlet;the contact member is a flexible barrier attached to the sidewall of the cryoprotectant vessel to form a cryoprotectant chamber, wherein the inlet and outlet of the cryoprotectant vessel are configured to direct a flow of liquid cryoprotectant through the cryoprotectant chamber; andthe cooling unit comprises a cold plate and a heat exchanger having a coolant chamber through which a coolant can flow, and wherein the cold plate is in contact with the backpanel of the cryoprotectant vessel.
  • 15. The application system of claim 13, wherein: the cryoprotectant vessel comprises a backpanel, a sidewall projecting from the backpanel, an inlet, an outlet, and a conduit having one portion connected to the inlet and another portion connected to the outlet;the contact member is a flexible barrier attached to the sidewall of the cryoprotectant vessel to form a cryoprotectant chamber, wherein the inlet and the outlet of the cryoprotectant vessel are configured to direct a flow of liquid cryoprotectant through the cryoprotectant chamber; andthe cooling unit is spaced apart from the cryoprotectant chamber and coupled to the conduit, and wherein the cooling unit cools the flow of liquid cryoprotectant.
  • 16. The application system of claim 1, wherein the array of selectably addressable heating elements is arranged in a grid, and individual heating elements of the array of selectably addressable heating elements can be independently controlled from each other.
  • 17. The application system of claim 16, further comprising an array of temperature sensors carried by the contact member, wherein individual heating elements of the array of selectably addressable heating elements are associated with at least one corresponding temperature sensor.
  • 18. The application system of claim 16, further comprising an array of temperature sensor sets carried by the contact member, wherein individual heating elements of the array of selectably addressable heating elements are associated with a corresponding temperature sensor set.
  • 19. The application system of claim 1, wherein the cooling unit comprises a backside heating element in thermal communication with the contact member.
  • 20. The application system of claim 1 wherein the array of selectably addressable heating elements is located directly between a chamber for holding the cryoprotectant and the front side of the contact member.
  • 21. The application system of claim 1 wherein the array of selectably addressable heating elements is configured and positioned to heat the subject's skin.
  • 22. The application system of claim 1, wherein the controller is programmed to adjust an amount of heat generated by one or more heating elements of the array of selectable heating elements while the cooling unit operates to cool the subcutaneous lipid-rich tissue so as to produce a heat flux profile or a temperature profile along the front side of the contact member sufficiently close to a target heat flux profile or a target temperature profile.
  • 23. An application assembly for cooling subcutaneous lipid-rich tissue, comprising: a cooling unit; a disposable interface assembly having a connector configured to retain the disposable interface assembly in contact with the cooling unit, a cryoprotectant vessel proximate the cooling unit such that a cryoprotectant is cooled to a desired base temperature, and an interface element having a contact member through which the cryoprotectant can pass, wherein the contact member includes a thermal gradient interface having one or more physical discontinuities configured to define one or more units of the thermal gradient interface, wherein each unit is associated with one of a plurality of selectably addressable heating elements arranged into an array and carried by the contact member; and a controller including a computer-operable medium programmed to cause the cooling unit to operate to cool subcutaneous lipid-rich tissue to disrupt subcutaneous lipid-rich cells and to cause one or more heating elements of the array of addressable heating elements to warm tissue while the cooling unit cools the subcutaneous lipid-rich tissue.
  • 24. A disposable interface assembly for an application system that cools subcutaneous lipid-rich tissue, comprising a cryoprotectant container having a cavity and an interface element enclosing one side of the cavity, wherein the interface element includes a flexible contact member and an array of selectably addressable heating elements carried by the flexible contact member, wherein the contact member includes a thermal gradient layer having one or more physical discontinuities configured to define one or more units of the thermal gradient layer, wherein each unit is associated with each of the selectably addressable heating elements and wherein the flexible contact member is configured to allow a cryoprotectant to flow through the flexible contact member.
  • 25. The disposable interface assembly of claim 24, further comprising a flowable cryoprotectant gel in the cavity.
  • 26. The disposable interface assembly of claim 24, further comprising a connector attached to the cryoprotectant container, wherein the connector is configured to retain the cryoprotectant container proximate to a cooling unit.
  • 27. The disposable interface assembly of claim 24, wherein the array of selectably addressable heating elements is positioned between the cavity and a patient-facing surface of the flexible contact and operable to warm a first region of tissue cooled by the application system while the applicator system cools a second region of tissue in contact with cryoprotectant that been delivered through the contact member.
  • 28. An application system for cooling subcutaneous lipid-rich tissue, comprising: a cooling unit; a cryoprotectant vessel configured to contain a cryoprotectant such that at least a portion of the cryoprotectant is cooled by the cooling unit to a desired cold temperature; a contact member including a backside positioned to contact the cryoprotectant in the cryoprotectant vessel and a front side opposite the backside, a thermal gradient layer having one or more physical discontinuities configured to define one or more units of the thermal gradient layer, wherein each unit is associated with one of a plurality of selectably addressable heating elements, and, wherein the contact member is configured to allow the cryoprotectant to flow from the backside to the front side; and wherein the selectably addressable heating elements are positioned between the cryoprotectant in the cryoprotectant vessel and the front side of the contact member; and a controller programmed to cause the cooling unit to operate to cool the subcutaneous lipid-rich tissue and programmed to independently control the selectably addressable heating elements to adjust an amount of heat generated by one or more of the selectably addressable heating elements to warm tissue cooled by the application system while the cooling unit operates to cool the subcutaneous lipid-rich tissue so as to produce a heat flux profile, a temperature profile, or a combination thereof along the front side of the contact member based on a target heat flux profile, a target temperature profile, or a combination thereof.
  • 29. The application system of claim 28, further comprising temperature sensors for monitoring operation of each of the selectably addressable heating elements, and wherein each of the temperature sensors is positioned directly between a respective one of the selectably addressable heating elements and a surface of the contact member at the front side of the contact member.
  • 30. An application system for cooling subcutaneous lipid-rich tissue, comprising: a cooling unit; a cryoprotectant vessel configured to contain a cryoprotectant such that at least a portion of the cryoprotectant is cooled by the cooling unit to a desired cold temperature; a contact member configured to be attached to the cryoprotectant vessel, the contact member including a backside configured to contact the cryoprotectant and a front side opposite the backside and a thermal gradient layer having one or more physical discontinuities configured to define one or more units of the thermal gradient layer, wherein each unit is associated with one of a plurality of selectably addressable heating elements, an array of the plurality of selectably addressable heating elements carried by the contact member, and wherein the contact member is configured to allow the cryoprotectant to flow from the backside to the front side; and a controller with a stored profile and being programmed to cause the application system to cool the subcutaneous lipid-rich tissue, and command one or more heating elements of the array of selectably addressable heating elements to warm tissue, which has been cooled by the application system, based on the stored profile while the application system cools the subcutaneous lipid-rich tissue to disrupt subcutaneous lipid-rich cells, wherein the stored profile includes a target heat flux profile, a target temperature profile, or a combination thereof.
  • 31. An application system for cooling subcutaneous lipid-rich tissue, comprising: a cooling unit having a contact member, the contact member having a thermal gradient layer including one or more physical discontinuities configured to define one or more thermal units in the thermal gradient layer, a plurality of selectably addressable heating elements carried by the contact member, wherein each thermal unit is associated with one or more of the selectably addressable heating elements; a cryoprotectant in contact with the contact member such that the cryoprotectant is cooled by the cooling unit to a desired cold temperature; and a controller with a stored profile and being programmed to cause the application system to cool the subcutaneous lipid-rich tissue, and command one or more heating elements of the array of selectably addressable heating elements to warm the subcutaneous lipid-rich tissue adjacent to the heating elements, which tissue has been cooled by the application system, based on the stored profile while the application system cools the subcutaneous lipid-rich tissue to disrupt subcutaneous lipid-rich cells, wherein the stored profile includes a target heat flux profile, a target temperature profile, or a combination thereof.
  • 32. The application system of claim 31, wherein the physical discontinuities and the selectably addressable heating elements define discrete heating regions along the cooling unit.
CROSS-REFERENCE TO RELATED APPLICATION(S)

This application claims priority to U.S. Provisional Patent Application No. 61/435,944, filed Jan. 25, 2011, entitled “DEVICES, APPLICATION SYSTEMS AND METHODS WITH LOCALIZED HEAT FLUX ZONES FOR REMOVING HEAT FROM SUBCUTANEOUS LIPID-RICH CELLS,” which is incorporated herein by reference in its entirety. The following commonly-assigned U.S. Patent Applications are incorporated herein by reference in their entirety: U.S. Patent Publication No. 2008/0287839 entitled “METHOD OF ENHANCED REMOVAL OF HEAT FROM SUBCUTANEOUS LIPID-RICH CELLS AND TREATMENT APPARATUS HAVING AN ACTUATOR”; U.S. Pat. No. 6,032,675 entitled “FREEZING METHOD FOR CONTROLLED REMOVAL OF FATTY TISSUE BY LIPOSUCTION”; U.S. Patent Publication No. 2007/0255362 entitled “CRYOPROTECTANT FOR USE WITH A TREATMENT DEVICE FOR IMPROVED COOLING OF SUBCUTANEOUS LIPID-RICH CELLS”; U.S. Pat. No. 7,854,754 entitled “COOLING DEVICE FOR REMOVING HEAT FROM SUBCUTANEOUS LIPID-RICH CELLS”; U.S. Patent Publication No. 2011/0066216 entitled “COOLING DEVICE FOR REMOVING HEAT FROM SUBCUTANEOUS LIPID-RICH CELLS”; U.S. Patent Publication No. 2008/0077201 entitled “COOLING DEVICES WITH FLEXIBLE SENSORS”; U.S. Patent Publication No. 2008/0077211 entitled “COOLING DEVICE HAVING A PLURALITY OF CONTROLLABLE COOLING ELEMENTS TO PROVIDE A PREDETERMINED COOLING PROFILE”; U.S. Patent Publication No. 2009/0118722, filed Oct. 31, 2007, entitled “METHOD AND APPARATUS FOR COOLING SUBCUTANEOUS LIPID-RICH CELLS OR TISSUE”; U.S. Patent Publication No. 2009/0018624 entitled “LIMITING USE OF DISPOSABLE SUBJECT 11 PROTECTION DEVICES”; U.S. Patent Publication No. 2009/0018623 entitled “SYSTEM FOR TREATING LIPID-RICH REGIONS”; U.S. Patent Publication No. 2009/0018625 entitled “MANAGING SYSTEM TEMPERATURE TO REMOVE HEAT FROM LIPID-RICH REGIONS”; U.S. Patent Publication No. 2009/0018627 entitled “SECURE SYSTEM FOR REMOVING HEAT FROM LIPID-RICH REGIONS”; U.S. Patent Publication No. 2009/0018626 entitled “USER INTERFACES FOR A SYSTEM THAT REMOVES HEAT FROM LIPID-RICH REGIONS”; U.S. Pat. No. 6,041,787 entitled “USE OF CRYOPROTECTIVE AGENT COMPOUNDS DURING CRYOSURGERY”; U.S. Patent Publication No. 2009/0149929 entitled “MONITORING THE COOLING OF SUBCUTANEOUS LIPID-RICH CELLS, SUCH AS THE COOLING OF ADIPOSE TISSUE”; U.S. Provisional Patent Application Ser. No. 60/941,567 entitled “METHODS, APPARATUSES AND SYSTEMS FOR COOLING THE SKIN AND SUBCUTANEOUS TISSUE”; U.S. Patent Publication No. 2010/0081971 entitled “TREATMENT PLANNING SYSTEMS AND METHODS FOR BODY CONTOURING APPLICATIONS”; U.S. patent application Ser. No. 12/275,002 entitled “APPARATUS WITH HYDROPHILIC RESERVOIRS FOR COOLING SUBCUTANEOUS LIPID-RICH CELLS”; U.S. patent application Ser. No. 12/275,014 entitled “APPARATUS WITH HYDROPHOBIC FILTERS FOR REMOVING HEAT FROM SUBCUTANEOUS LIPID-RICH CELLS”; U.S. Patent Publication No. 2010/0152824 entitled “SYSTEMS AND METHODS WITH INTERRUPT/RESUME CAPABILITIES FOR COOLING SUBCUTANEOUS LIPID-RICH CELLS”; U.S. Patent Publication No. 2008/0077202 entitled “TISSUE TREATMENT METHODS”; U.S. Patent Publication No. 2010/0280582 entitled “DEVICE, SYSTEM AND METHOD FOR REMOVING HEAT FROM SUBCUTANEOUS LIPID-RICH CELLS”; U.S. patent application Ser. No. 12/840,235 entitled “COMBINED MODALITY TREATMENT SYSTEMS, METHODS AND APPARATUS FOR BODY CONTOURING APPLICATIONS”; U.S. Publication No. 2011/0238050 entitled “HOME-USE APPLICATORS FOR NON-INVASIVELY REMOVING HEAT FROM SUBCUTANEOUS LIPID-RICH CELLS VIA PHASE CHANGE COOLANTS, AND ASSOCIATED DEVICES, SYSTEMS AND METHODS”; and U.S. Publication No. 2011/0238051 entitled “HOME-USE APPLICATORS FOR NON-INVASIVELY REMOVING HEAT FROM SUBCUTANEOUS LIPID-RICH CELLS VIA PHASE CHANGE COOLANTS, AND ASSOCIATED DEVICES, SYSTEMS AND METHODS”.

US Referenced Citations (545)
Number Name Date Kind
681806 Mignault Sep 1901 A
889810 Robinson Jun 1908 A
2516491 Swastek Jul 1950 A
2521780 Dodd et al. Sep 1950 A
3093135 Hirschhorn Jun 1963 A
3132688 Nowak May 1964 A
3133539 William et al. May 1964 A
3282267 Wiliam Nov 1966 A
3502080 Hirschhorn Mar 1970 A
3587577 Smirnov et al. Jun 1971 A
3591645 Selwitz Jul 1971 A
3703897 Mack et al. Nov 1972 A
3710784 Taylor Jan 1973 A
3786814 Armao Jan 1974 A
3827436 Stumpf et al. Aug 1974 A
3942519 Shock Mar 1976 A
3948269 Zimmer Apr 1976 A
3986385 Johnston et al. Oct 1976 A
4002221 Buchalter Jan 1977 A
4026299 Sauder May 1977 A
4140130 Storm, III Feb 1979 A
4178429 Scheffer Dec 1979 A
4202336 van Gerven et al. May 1980 A
4266043 Fujii et al. May 1981 A
4381009 Del Bon et al. Apr 1983 A
4396011 Mack et al. Aug 1983 A
4483341 Witteles Nov 1984 A
4528979 Marchenko et al. Jul 1985 A
4531524 Mioduski Jul 1985 A
4548212 Leung Oct 1985 A
4555313 Duchane et al. Nov 1985 A
4585002 Kissin Apr 1986 A
4603076 Bowditch et al. Jul 1986 A
4614191 Perler Sep 1986 A
4644955 Mioduski Feb 1987 A
4664110 Schanzlin May 1987 A
4700701 Montaldi Oct 1987 A
4718429 Smidt et al. Jan 1988 A
4741338 Miyamae et al. May 1988 A
4764463 Mason et al. Aug 1988 A
4802475 Weshahy et al. Feb 1989 A
4832022 Tjulkov et al. May 1989 A
4846176 Golden Jul 1989 A
4850340 Onishi Jul 1989 A
4869250 Bitterly Sep 1989 A
4880564 Abel et al. Nov 1989 A
4905697 Heggs et al. Mar 1990 A
4906463 Cleary et al. Mar 1990 A
4930317 Klein Jun 1990 A
4935345 Guibeau et al. Jun 1990 A
4961422 Marchosky et al. Oct 1990 A
4962761 Golden Oct 1990 A
4990144 Blott Feb 1991 A
5007433 Hermsdorffer et al. Apr 1991 A
5018521 Campbell May 1991 A
5024650 Hagiwara et al. Jun 1991 A
5065752 Sessions et al. Nov 1991 A
5069208 Noppel et al. Dec 1991 A
5084671 Miyata et al. Jan 1992 A
5108390 Potocky et al. Apr 1992 A
5119674 Nielsen et al. Jun 1992 A
5139496 Hed et al. Aug 1992 A
5143063 Fellner Sep 1992 A
5148804 Hill et al. Sep 1992 A
5158070 Dory Oct 1992 A
5169384 Bosniak et al. Dec 1992 A
5197466 Marchosky et al. Mar 1993 A
5207674 Hamilton May 1993 A
5221726 Dabi et al. Jun 1993 A
5264234 Windhab et al. Nov 1993 A
5277030 Miller Jan 1994 A
5314423 Seney May 1994 A
5327886 Chiu Jul 1994 A
5330745 McDow Jul 1994 A
5334131 Omandam et al. Aug 1994 A
5336616 Livesey et al. Aug 1994 A
5339541 Owens Aug 1994 A
5342617 Gold Aug 1994 A
5351677 Kami et al. Oct 1994 A
5358467 Milstein et al. Oct 1994 A
5362966 Rosenthal et al. Nov 1994 A
5372608 Johnson Dec 1994 A
5386837 Sterzer Feb 1995 A
5411541 Bell et al. May 1995 A
5427772 Hagan Jun 1995 A
5433717 Rubinsky et al. Jul 1995 A
5456703 Beeuwkes, III Oct 1995 A
5472416 Blugerman et al. Dec 1995 A
5486207 Mahawili Jan 1996 A
5497596 Zatkulak Mar 1996 A
5505726 Meserol Apr 1996 A
5505730 Edwards Apr 1996 A
5507790 Weiss et al. Apr 1996 A
5514105 Goodman, Jr. et al. May 1996 A
5514170 Mauch May 1996 A
5516505 McDow May 1996 A
5531742 Barken Jul 1996 A
5562604 Yablon et al. Oct 1996 A
5571801 Segall et al. Nov 1996 A
5575812 Owens et al. Nov 1996 A
5603221 Maytal et al. Feb 1997 A
5628769 Saringer et al. May 1997 A
5634890 Morris Jun 1997 A
5634940 Panyard Jun 1997 A
5647051 Neer Jul 1997 A
5647868 Chinn Jul 1997 A
5650450 Lovette et al. Jul 1997 A
5651773 Perry et al. Jul 1997 A
5654279 Rubinsky et al. Aug 1997 A
5654546 Lindsay Aug 1997 A
5660836 Knowlton Aug 1997 A
5665053 Jacobs Sep 1997 A
5672172 Zupkas Sep 1997 A
5700284 Owens et al. Dec 1997 A
5725483 Podolsky Mar 1998 A
5733280 Avitall Mar 1998 A
5741248 Stern et al. Apr 1998 A
5746736 Tankovich May 1998 A
5755663 Larsen et al. May 1998 A
5755753 Knowlton May 1998 A
5755755 Panyard May 1998 A
5759182 Varney et al. Jun 1998 A
5759764 Polovina Jun 1998 A
5769879 Richards et al. Jun 1998 A
5785955 Fischer Jul 1998 A
5792080 Ookawa et al. Aug 1998 A
5814040 Nelson et al. Sep 1998 A
5817050 Klein Oct 1998 A
5817149 Owens et al. Oct 1998 A
5817150 Owens et al. Oct 1998 A
5830208 Muller Nov 1998 A
5833685 Tortal et al. Nov 1998 A
5844013 Kenndoff et al. Dec 1998 A
5871524 Knowlton Feb 1999 A
5871526 Gibbs et al. Feb 1999 A
5885211 Eppstein et al. Mar 1999 A
5895418 Saringer et al. Apr 1999 A
5901707 Goncalves et al. May 1999 A
5902256 Benaron May 1999 A
5919219 Knowlton Jul 1999 A
5944748 Mager et al. Aug 1999 A
5948011 Knowlton Sep 1999 A
5954680 Augustine et al. Sep 1999 A
5964092 Tozuka et al. Oct 1999 A
5964749 Eckhouse et al. Oct 1999 A
5967976 Larsen et al. Oct 1999 A
5986167 Arteman et al. Nov 1999 A
5989286 Owens et al. Nov 1999 A
5997530 Nelson et al. Dec 1999 A
6017337 Pira et al. Jan 2000 A
6023932 Johnston et al. Feb 2000 A
6032675 Rubinsky Mar 2000 A
6039694 Larson et al. Mar 2000 A
6041787 Rubinsky Mar 2000 A
6049927 Thomas et al. Apr 2000 A
6051159 Hao et al. Apr 2000 A
6074415 Der Ovanesian Jun 2000 A
6093230 Johnson, III et al. Jul 2000 A
6102885 Bass Aug 2000 A
6104952 Tu et al. Aug 2000 A
6104959 Spertell et al. Aug 2000 A
6106517 Zupkas Aug 2000 A
6113558 Rosenschein et al. Sep 2000 A
6113559 Klopotek Sep 2000 A
6113626 Clifton et al. Sep 2000 A
6120519 Weber et al. Sep 2000 A
6151735 Koby et al. Nov 2000 A
6152952 Owens et al. Nov 2000 A
6171301 Nelson et al. Jan 2001 B1
6226996 Weber et al. May 2001 B1
6241753 Knowlton Jun 2001 B1
6264649 Whitcroft et al. Jul 2001 B1
6273884 Altshuler et al. Aug 2001 B1
6290988 Van Vilsteren et al. Sep 2001 B1
6311090 Knowlton Oct 2001 B1
6311497 Chung et al. Nov 2001 B1
6312453 Stefanile et al. Nov 2001 B1
6350276 Knowlton Feb 2002 B1
6354297 Eiseman Mar 2002 B1
6357907 Cleveland et al. Mar 2002 B1
6375673 Clifton et al. Apr 2002 B1
6377854 Knowlton Apr 2002 B1
6377855 Knowlton Apr 2002 B1
6381497 Knowlton Apr 2002 B1
6381498 Knowlton Apr 2002 B1
6387380 Knowlton May 2002 B1
6401722 Krad Jun 2002 B1
6405090 Knowlton Jun 2002 B1
6413255 Stern Jul 2002 B1
6425912 Knowlton Jul 2002 B1
6426445 Young et al. Jul 2002 B1
6430446 Knowlton Aug 2002 B1
6430956 Haas et al. Aug 2002 B1
6438424 Knowlton Aug 2002 B1
6438964 Giblin Aug 2002 B1
6453202 Knowlton Sep 2002 B1
6458888 Hood et al. Oct 2002 B1
6461378 Knowlton Oct 2002 B1
6470216 Knowlton Oct 2002 B1
6471693 Carroll et al. Oct 2002 B1
6475211 Chess et al. Nov 2002 B2
6494844 Van Bladel et al. Dec 2002 B1
6497721 Ginsburg et al. Dec 2002 B2
6508831 Kushnir Jan 2003 B1
6514244 Pope et al. Feb 2003 B2
6519964 Bieberich Feb 2003 B2
6523354 Tolbert Feb 2003 B1
6527765 Kelman et al. Mar 2003 B2
6527798 Ginsburg et al. Mar 2003 B2
6544248 Bass Apr 2003 B1
6548297 Kuri-Harcuch et al. Apr 2003 B1
6551348 Blalock et al. Apr 2003 B1
6551349 Lasheras et al. Apr 2003 B2
6569189 Augustine et al. May 2003 B1
6585652 Lang et al. Jul 2003 B2
6592577 Abboud et al. Jul 2003 B2
6605080 Altshuler et al. Aug 2003 B1
6620188 Ginsburg et al. Sep 2003 B1
6620189 Machold et al. Sep 2003 B1
6623430 Slayton et al. Sep 2003 B1
6626854 Friedman et al. Sep 2003 B2
6632219 Baranov et al. Oct 2003 B1
6635053 Lalonde et al. Oct 2003 B1
6645162 Friedman et al. Nov 2003 B2
6645229 Matsumura et al. Nov 2003 B2
6648904 Altshuler et al. Nov 2003 B2
6656208 Grahn et al. Dec 2003 B2
6662054 Kreindel et al. Dec 2003 B2
6682550 Clifton et al. Jan 2004 B2
6685731 Kushnir et al. Feb 2004 B2
6695874 Machold et al. Feb 2004 B2
6699266 Lachenbruch et al. Mar 2004 B2
6718785 Bieberich Apr 2004 B2
6741895 Gafni et al. May 2004 B1
6743222 Durkin et al. Jun 2004 B2
6746474 Saadat Jun 2004 B2
6749624 Knowlton Jun 2004 B2
6764493 Weber et al. Jul 2004 B1
6764502 Bieberich Jul 2004 B2
6789545 Littrup et al. Sep 2004 B2
6820961 Johnson Nov 2004 B2
6821274 McHale et al. Nov 2004 B2
6840955 Ein Jan 2005 B2
6849075 Bertolero et al. Feb 2005 B2
6878144 Altshuler et al. Apr 2005 B2
6889090 Kreindel May 2005 B2
6904956 Noel Jun 2005 B2
6918903 Bass Jul 2005 B2
6927316 Faries, Jr. et al. Aug 2005 B1
6942022 Blangetti et al. Sep 2005 B2
6945942 Van Bladel et al. Sep 2005 B2
6948903 Ablabutyan et al. Sep 2005 B2
7005558 Johansson et al. Feb 2006 B1
7022121 Stern et al. Apr 2006 B2
7037326 Lee et al. May 2006 B2
7060061 Altshuler et al. Jun 2006 B2
7077858 Fletcher et al. Jul 2006 B2
7081111 Svaasand et al. Jul 2006 B2
7096204 Chen et al. Aug 2006 B1
7112712 Ancell Sep 2006 B1
7115123 Knowlton et al. Oct 2006 B2
7183360 Daniel et al. Feb 2007 B2
7189252 Krueger Mar 2007 B2
7192426 Baust et al. Mar 2007 B2
7204832 Altshuler et al. Apr 2007 B2
7220778 Anderson et al. May 2007 B2
7258674 Cribbs et al. Aug 2007 B2
7276058 Altshuler et al. Oct 2007 B2
7367341 Anderson et al. May 2008 B2
7572268 Babaev Aug 2009 B2
7604632 Howlett et al. Oct 2009 B2
7613523 Eggers et al. Nov 2009 B2
7615016 Barthe et al. Nov 2009 B2
7713266 Elkins et al. May 2010 B2
7780656 Tankovich Aug 2010 B2
7799018 Goulko Sep 2010 B2
7824437 Saunders Nov 2010 B1
7850683 Elkins et al. Dec 2010 B2
7854754 Ting et al. Dec 2010 B2
7862558 Elkins et al. Jan 2011 B2
7959657 Harsy et al. Jun 2011 B1
7963959 Da Silva et al. Jun 2011 B2
7993330 Goulko Aug 2011 B2
7998137 Elkins et al. Aug 2011 B2
8133180 Slayton et al. Mar 2012 B2
8246611 Paithankar et al. Aug 2012 B2
8333700 Barthe et al. Dec 2012 B1
8366622 Slayton et al. Feb 2013 B2
8372130 Young et al. Feb 2013 B2
8397518 Vistakula et al. Mar 2013 B1
8414631 Quisenberry et al. Apr 2013 B2
8433400 Prushinskaya et al. Apr 2013 B2
8506486 Slayton et al. Aug 2013 B2
8523775 Barthe et al. Sep 2013 B2
8523791 Castel Sep 2013 B2
8523927 Levinson et al. Sep 2013 B2
8535228 Slayton et al. Sep 2013 B2
8603073 Allison Dec 2013 B2
8636665 Slayton et al. Jan 2014 B2
8641622 Barthe et al. Feb 2014 B2
8663112 Slayton et al. Mar 2014 B2
8672848 Slayton et al. Mar 2014 B2
8676332 Fahey Mar 2014 B2
8690778 Slayton et al. Apr 2014 B2
8690779 Slayton et al. Apr 2014 B2
8690780 Slayton et al. Apr 2014 B2
8702774 Baker et al. Apr 2014 B2
8758215 Legendre et al. Jun 2014 B2
8764693 Graham et al. Jul 2014 B1
8834547 Anderson et al. Sep 2014 B2
20010005791 Ginsburg et al. Jun 2001 A1
20010007952 Shimizu Jul 2001 A1
20010023364 Ahn Sep 2001 A1
20010031459 Fahy et al. Oct 2001 A1
20010039439 Elkins et al. Nov 2001 A1
20010045104 Bailey et al. Nov 2001 A1
20010047196 Ginsburg et al. Nov 2001 A1
20020026226 Ein Feb 2002 A1
20020032473 Kushnir et al. Mar 2002 A1
20020042607 Palmer et al. Apr 2002 A1
20020049483 Knowlton Apr 2002 A1
20020058975 Bieberich May 2002 A1
20020062142 Knowlton May 2002 A1
20020082668 Ingman Jun 2002 A1
20020103520 Latham Aug 2002 A1
20020107558 Clifton et al. Aug 2002 A1
20020117293 Campbell Aug 2002 A1
20020151830 Kahn Oct 2002 A1
20020151887 Stern et al. Oct 2002 A1
20020156509 Cheung Oct 2002 A1
20020188286 Quijano et al. Dec 2002 A1
20030032900 Ella Feb 2003 A1
20030044764 Soane et al. Mar 2003 A1
20030055414 Altshuler et al. Mar 2003 A1
20030062040 Lurie et al. Apr 2003 A1
20030069618 Smith et al. Apr 2003 A1
20030077329 Kipp et al. Apr 2003 A1
20030079488 Bieberich May 2003 A1
20030100936 Altshuler et al. May 2003 A1
20030109908 Lachenbruch et al. Jun 2003 A1
20030109910 Lachenbruch et al. Jun 2003 A1
20030109911 Lachenbruch et al. Jun 2003 A1
20030114885 Nova et al. Jun 2003 A1
20030120268 Bertolero et al. Jun 2003 A1
20030125649 McIntosh et al. Jul 2003 A1
20030187488 Kreindel et al. Oct 2003 A1
20030199226 Sommer et al. Oct 2003 A1
20030199859 Altshuler et al. Oct 2003 A1
20030220594 Halvorson et al. Nov 2003 A1
20030220674 Anderson et al. Nov 2003 A1
20030236487 Knowlton Dec 2003 A1
20040006328 Anderson Jan 2004 A1
20040009936 Tang et al. Jan 2004 A1
20040024437 Machold et al. Feb 2004 A1
20040030332 Knowlton et al. Feb 2004 A1
20040034341 Altshuler et al. Feb 2004 A1
20040039312 Hillstead et al. Feb 2004 A1
20040044384 Leber et al. Mar 2004 A1
20040049178 Abboud et al. Mar 2004 A1
20040073079 Altshuler et al. Apr 2004 A1
20040074629 Noel Apr 2004 A1
20040077977 Ella et al. Apr 2004 A1
20040082886 Timpson Apr 2004 A1
20040093042 Altshuler et al. May 2004 A1
20040104012 Zhou et al. Jun 2004 A1
20040106867 Eshel et al. Jun 2004 A1
20040133251 Altshuler et al. Jul 2004 A1
20040162596 Altshuler et al. Aug 2004 A1
20040199226 Shadduck Oct 2004 A1
20040210214 Knowlton Oct 2004 A1
20040210287 Greene Oct 2004 A1
20040249427 Nabilsi et al. Dec 2004 A1
20040259855 Anderson et al. Dec 2004 A1
20040260209 Ella et al. Dec 2004 A1
20040260210 Ella et al. Dec 2004 A1
20040260211 Maalouf Dec 2004 A1
20050010197 Lau et al. Jan 2005 A1
20050049526 Baer Mar 2005 A1
20050049543 Anderson et al. Mar 2005 A1
20050049661 Koffroth Mar 2005 A1
20050113725 Masuda May 2005 A1
20050145372 Noel Jul 2005 A1
20050154431 Quistgaard et al. Jul 2005 A1
20050159986 Breeland et al. Jul 2005 A1
20050177075 Meunier et al. Aug 2005 A1
20050182462 Chornenky et al. Aug 2005 A1
20050187597 Vanderschuit Aug 2005 A1
20050203446 Takashima Sep 2005 A1
20050215987 Slatkine Sep 2005 A1
20050222565 Manstein Oct 2005 A1
20050251117 Anderson et al. Nov 2005 A1
20050251120 Anderson et al. Nov 2005 A1
20050277859 Carlsmith et al. Dec 2005 A1
20050283144 Shiono et al. Dec 2005 A1
20060030778 Mendlein et al. Feb 2006 A1
20060036300 Kreindel Feb 2006 A1
20060074313 Slayton et al. Apr 2006 A1
20060079852 Bubb et al. Apr 2006 A1
20060122509 Desilets Jun 2006 A1
20060189964 Anderson et al. Aug 2006 A1
20060195168 Dunbar et al. Aug 2006 A1
20060200063 Munro et al. Sep 2006 A1
20060206040 Greenberg et al. Sep 2006 A1
20060234899 Nekmard et al. Oct 2006 A1
20060259102 Slatkine Nov 2006 A1
20060270745 Hunt et al. Nov 2006 A1
20060293734 Scott et al. Dec 2006 A1
20070010861 Anderson et al. Jan 2007 A1
20070032561 Lin et al. Feb 2007 A1
20070038156 Rosenberg Feb 2007 A1
20070073367 Jones et al. Mar 2007 A1
20070088413 Weber Apr 2007 A1
20070129714 Elkins et al. Jun 2007 A1
20070135876 Weber Jun 2007 A1
20070141265 Thomson Jun 2007 A1
20070179482 Anderson et al. Aug 2007 A1
20070198071 Ting et al. Aug 2007 A1
20070239075 Rosenberg et al. Oct 2007 A1
20070249519 Guha et al. Oct 2007 A1
20070255187 Branch Nov 2007 A1
20070255362 Levinson Nov 2007 A1
20070265585 Joshi et al. Nov 2007 A1
20070270925 Levinson Nov 2007 A1
20070282249 Quisenberry et al. Dec 2007 A1
20080046047 Jacobs Feb 2008 A1
20080058784 Manstein et al. Mar 2008 A1
20080077201 Levinson et al. Mar 2008 A1
20080077202 Levinson Mar 2008 A1
20080077211 Levinson et al. Mar 2008 A1
20080097207 Cai et al. Apr 2008 A1
20080139901 Altshuler et al. Jun 2008 A1
20080140061 Toubia et al. Jun 2008 A1
20080140371 Warner Jun 2008 A1
20080161892 Mercuro et al. Jul 2008 A1
20080183164 Elkins et al. Jul 2008 A1
20080188915 Mills Aug 2008 A1
20080269851 Deem et al. Oct 2008 A1
20080287839 Rosen et al. Nov 2008 A1
20090012434 Anderson Jan 2009 A1
20090018623 Levinson et al. Jan 2009 A1
20090018624 Levinson et al. Jan 2009 A1
20090018625 Levinson et al. Jan 2009 A1
20090018626 Levinson et al. Jan 2009 A1
20090018627 Levinson et al. Jan 2009 A1
20090112134 Avni Apr 2009 A1
20090118722 Ebbers May 2009 A1
20090149929 Levinson et al. Jun 2009 A1
20090149930 Schenck Jun 2009 A1
20090171334 Elkins et al. Jul 2009 A1
20090276018 Brader Nov 2009 A1
20090299234 Cho et al. Dec 2009 A1
20090312676 Rousso et al. Dec 2009 A1
20090312693 Thapliyal et al. Dec 2009 A1
20100015190 Hassler Jan 2010 A1
20100030306 Edelman et al. Feb 2010 A1
20100036295 Altshuler et al. Feb 2010 A1
20100042087 Goldboss et al. Feb 2010 A1
20100049178 Deem et al. Feb 2010 A1
20100081971 Allison Apr 2010 A1
20100087806 Da Silva et al. Apr 2010 A1
20100152824 Allison Jun 2010 A1
20100168726 Brookman Jul 2010 A1
20100179531 Nebrigic Jul 2010 A1
20100198064 Perl et al. Aug 2010 A1
20100217349 Fahey et al. Aug 2010 A1
20100268220 Johnson et al. Oct 2010 A1
20100280582 Baker et al. Nov 2010 A1
20110040235 Castel Feb 2011 A1
20110040299 Kim et al. Feb 2011 A1
20110046523 Altshuler et al. Feb 2011 A1
20110060323 Baust et al. Mar 2011 A1
20110066083 Tosaya et al. Mar 2011 A1
20110077557 Wing et al. Mar 2011 A1
20110077723 Parish et al. Mar 2011 A1
20110112520 Kreindel May 2011 A1
20110144631 Elkins et al. Jun 2011 A1
20110152849 Baust et al. Jun 2011 A1
20110172651 Altshuler et al. Jul 2011 A1
20110189129 Qiu et al. Aug 2011 A1
20110196395 Maschke Aug 2011 A1
20110202048 Nebrigic Aug 2011 A1
20110257642 Griggs, III Oct 2011 A1
20110301585 Goulko Dec 2011 A1
20110313411 Anderson et al. Dec 2011 A1
20110313412 Kim et al. Dec 2011 A1
20120010609 Deem et al. Jan 2012 A1
20120022518 Levinson Jan 2012 A1
20120022622 Johnson et al. Jan 2012 A1
20120065629 Elkins et al. Mar 2012 A1
20120083862 Altshuler et al. Apr 2012 A1
20120109041 Munz May 2012 A1
20120158100 Schomacker Jun 2012 A1
20120209363 Williams, III et al. Aug 2012 A1
20120233736 Tepper et al. Sep 2012 A1
20120253416 Erez et al. Oct 2012 A1
20120259322 Fourkas et al. Oct 2012 A1
20120277674 Clark, III et al. Nov 2012 A1
20120310232 Erez Dec 2012 A1
20130018236 Altshuler et al. Jan 2013 A1
20130019374 Schwartz Jan 2013 A1
20130073017 Liu et al. Mar 2013 A1
20130079684 Rosen et al. Mar 2013 A1
20130150844 Deem et al. Jun 2013 A1
20130166003 Johnson et al. Jun 2013 A1
20130190744 Avram et al. Jul 2013 A1
20130238062 Ron Edoute et al. Sep 2013 A1
20130245507 Khorassani Zadeh Sep 2013 A1
20130253384 Anderson et al. Sep 2013 A1
20130253493 Anderson et al. Sep 2013 A1
20130253494 Anderson et al. Sep 2013 A1
20130253495 Anderson et al. Sep 2013 A1
20130253496 Anderson et al. Sep 2013 A1
20130331914 Lee et al. Dec 2013 A1
20140005759 Fahey et al. Jan 2014 A1
20140005760 Levinson et al. Jan 2014 A1
20140067025 Levinson et al. Mar 2014 A1
20140142469 Britva et al. May 2014 A1
20140200487 Ramdas et al. Jul 2014 A1
20140200488 Seo et al. Jul 2014 A1
20140222121 Spence et al. Aug 2014 A1
20140277219 Nanda Sep 2014 A1
20140277302 Weber et al. Sep 2014 A1
20140277303 Biser et al. Sep 2014 A1
20140303697 Anderson et al. Oct 2014 A1
20150209174 Abreu Jul 2015 A1
20150216719 DeBenedictis et al. Aug 2015 A1
20150216720 DeBenedictis et al. Aug 2015 A1
20150216816 O'Neil et al. Aug 2015 A1
20150223975 Anderson et al. Aug 2015 A1
20150328077 Levinson Nov 2015 A1
20150335468 Rose et al. Nov 2015 A1
20150342780 Levinson et al. Dec 2015 A1
20160051308 Pennybacker et al. Feb 2016 A1
20160051401 Yee et al. Feb 2016 A1
20160135985 Anderson May 2016 A1
20160324684 Levinson et al. Nov 2016 A1
20170079833 Frangineas, Jr. et al. Mar 2017 A1
20170105869 Frangineas, Jr. et al. Apr 2017 A1
20170165105 Anderson et al. Jun 2017 A1
20170196731 Debenedictis et al. Jul 2017 A1
20170239079 Root et al. Aug 2017 A1
20170325992 DeBenedictis et al. Nov 2017 A1
20170325993 Jimenez Lozano et al. Nov 2017 A1
20170326042 Zeng et al. Nov 2017 A1
20170326346 Jimenez Lozano et al. Nov 2017 A1
Foreign Referenced Citations (154)
Number Date Country
2011253768 Jun 2012 AU
2441489 Mar 2005 CA
333982 Nov 1958 CH
86200604 Oct 1987 CN
2514795 Oct 2002 CN
1511503 Jul 2004 CN
1741777 Mar 2006 CN
1817990 Aug 2006 CN
2843367 Dec 2006 CN
2850584 Dec 2006 CN
2850585 Dec 2006 CN
200970265 Nov 2007 CN
532976 Sep 1931 DE
2851602 Jun 1980 DE
4213584 Nov 1992 DE
4224595 Jan 1994 DE
4238291 May 1994 DE
4445627 Jun 1996 DE
19800416 Jul 1999 DE
0263069 Apr 1988 EP
0397043 Nov 1990 EP
0406244 Jan 1991 EP
0598824 Jun 1994 EP
1030611 Aug 2000 EP
1568395 Aug 2005 EP
2260801 Dec 2010 EP
2289598 Mar 2011 EP
2527005 Nov 2012 EP
854937 Apr 1940 FR
2744358 Aug 1997 FR
2767476 Feb 1999 FR
2776920 Oct 1999 FR
2789893 Aug 2000 FR
2805989 Sep 2001 FR
387960 Feb 1933 GB
2120944 Dec 1983 GB
2248183 Apr 1992 GB
2263872 Aug 1993 GB
2286660 Aug 1995 GB
2323659 Sep 1998 GB
63076895 Apr 1988 JP
01223961 Sep 1989 JP
10223961 Sep 1989 JP
03051964 Mar 1991 JP
3259975 Nov 1991 JP
4093597 Mar 1992 JP
6282977 Oct 1994 JP
7194666 Aug 1995 JP
7268274 Oct 1995 JP
09164163 Jun 1997 JP
10216169 Aug 1998 JP
3065657 Nov 1999 JP
2000503154 Mar 2000 JP
2001046416 Feb 2001 JP
2002543668 Dec 2002 JP
2004013600 Jan 2004 JP
2004159666 Jun 2004 JP
2004073812 Nov 2004 JP
2005039790 Feb 2005 JP
3655820 Mar 2005 JP
200565984 Mar 2005 JP
2005110755 Apr 2005 JP
2005520608 Jul 2005 JP
2005237908 Sep 2005 JP
2008323716 Nov 2005 JP
2006026001 Feb 2006 JP
2006130055 May 2006 JP
2005520608 Jul 2006 JP
2006520949 Sep 2006 JP
2008532591 Aug 2008 JP
2009189757 Aug 2009 JP
200173222 Dec 1999 KR
102004009450 Nov 2004 KR
20090000258 Jan 2009 KR
1020130043299 Apr 2013 KR
1020140038165 Mar 2014 KR
2036667 01 Jun 1995 RU
532976 Nov 1978 SU
0476644 Feb 2002 TW
WO1985003216 Aug 1985 WO
WO9705828 Nov 1990 WO
9114417 Oct 1991 WO
WO9404116 Mar 1994 WO
9623447 Aug 1996 WO
9626693 Sep 1996 WO
WO-9636293 Nov 1996 WO
WO-9637158 Nov 1996 WO
WO9637158 Nov 1996 WO
WO9636293 Nov 1996 WO
9704832 Feb 1997 WO
WO9705828 Feb 1997 WO
WO-9705828 Feb 1997 WO
WO9722262 Jun 1997 WO
WO-9722262 Jun 1997 WO
9724088 Jul 1997 WO
9748440 Dec 1997 WO
9829134 Jul 1998 WO
9831321 Jul 1998 WO
WO-9841157 Sep 1998 WO
WO-9841156 Sep 1998 WO
WO9841157 Sep 1998 WO
9909928 Mar 1999 WO
9916502 Apr 1999 WO
WO9938469 Aug 1999 WO
WO-9938469 Aug 1999 WO
9949937 Oct 1999 WO
WO-0044346 Aug 2000 WO
WO2000067685 Nov 2000 WO
0100269 Jan 2001 WO
0113989 Mar 2001 WO
WO0114012 Mar 2001 WO
WO2001014012 Mar 2001 WO
0134048 May 2001 WO
WO-0205736 Jan 2002 WO
WO-02102921 Dec 2002 WO
WO-200307859 Jan 2003 WO
WO-03078596 Sep 2003 WO
03079916 Oct 2003 WO
WO-04000098 Dec 2003 WO
WO-04080279 Sep 2004 WO
WO-05046540 May 2005 WO
2005060354 Jul 2005 WO
WO2005096979 Oct 2005 WO
2005112815 Dec 2005 WO
WO-06066226 Jun 2006 WO
WO2006094348 Sep 2006 WO
2006116603 Nov 2006 WO
WO-06127467 Nov 2006 WO
2007028975 Mar 2007 WO
WO-07041642 Apr 2007 WO
WO2007127924 Nov 2007 WO
2007145421 Dec 2007 WO
2007145422 Dec 2007 WO
2008006018 Jan 2008 WO
2008039556 Apr 2008 WO
WO2008039557 Apr 2008 WO
2008055243 May 2008 WO
WO2008143678 Nov 2008 WO
WO-2010077841 Jul 2010 WO
WO-2010127315 Nov 2010 WO
WO-2012012296 Jan 2012 WO
2013013059 Jan 2013 WO
2013075006 May 2013 WO
2013075016 May 2013 WO
2013190337 Dec 2013 WO
2014151872 Sep 2014 WO
2014191263 Dec 2014 WO
2015117001 Aug 2015 WO
2015117005 Aug 2015 WO
2015117026 Aug 2015 WO
2015117032 Aug 2015 WO
2015117036 Aug 2015 WO
2016028796 Feb 2016 WO
2016048721 Mar 2016 WO
Non-Patent Literature Citations (108)
Entry
European Search Report, European Patent Application No. EP07761461; Applicant: Zeltiq Aesthetics, Inc., dated Apr. 25, 2012, 9 pages.
European Search Report, Supplement, European Patent Application No. EP08798416.7, Applicant: Zeltiq Aesthetics, Inc., dated Jan. 12, 2012, 7 pages.
European Search Report, Supplement, European Patent Application No. EP09836823, Applicant: Zeltiq Aesthetics, Inc., dated May 15, 2012, 5 pages.
Final Office Action; U.S. Appl. No. 11/741,271; dated Jul. 19, 2012, 8 pages.
Final Office Action; U.S. Appl. No. 11/750,953; dated Jul. 5, 2012, 11 pages.
International Search Report and Written Opinion for PCT/US2012/022585; dated May 18, 2012, 12 pages.
Non-Final Office Action; U.S. Appl. No. 11/528,189; dated Apr. 6, 2012, 9 pages.
Non-Final Office Action; U.S. Appl. No. 11/777,992; dated Jun. 22, 2012, 5 pages.
Pre-Interview Office Action; U.S. Appl. No. 11/434,478; dated May 6, 2010, 4 pages.
Ardevol, “Cooling rates of tissue samples during freezing with liquid nitrogen,” J. of Biochem and Biophysical Methods, 27, 77-86 (1993).
Bohm et al., “Saline-enhanced radiofrequency ablation of breast tissue: an in vitro feasibility study,” Invest Radiol, 2000, pp. 149-57, vol. 35—issue (3).
Bondei, E. et al., “Disorders of Subcutaneous Tissue (Cold Panniculitis),” Dermatology in General Medicine, Chapter 108, Section 16: 1333-1334, 1993.
Burge, S.M. et al., “Hair Follicle Destruction and Regeneration in Guinea Pig Skin after Cutaneous Freeze Injury,” Cryobiology, 27(2): 153-163, 1990.
Coban, “Ischemia-Reperfusion Injury of Adipofascial Tissue: An Experimental Study Evaluating early Histologic and Biochemical Alterations in Rats,” Mediators of Inflammation, 2005, 5, 304-308.
Disclosure re: “Method and Apparatus for Regional Fat Reduction Using Controlled and Sustained Cooling of Skin Surface”.
Donski et al., “The Effects of Cooling no Experimental Free Flap Survival,” Brit J Plas Surg, 1980, pp. 353-360, vol. 33.
Duncan, W.C. et al., “Cold Panniculitis,” Arch. Derm., 94:722-24, 1966.
Epstein, E.H. et al., “Popsicle Panniculitis,” The New England Journal of Medicine, 282(17):996-67, 1970.
European Search Report, European Patent Application No. 10167756.5, Applicant: The General Hospital Corporation, dated Aug. 31, 2010, 6 pages.
Final Office Action; U.S. Appl. No. 10/391,221; dated Aug. 24, 2006, 4 pages.
Final Office Action; U.S. Appl. No. 11/016,196; dated Mar. 23, 2010, 12 pages.
Final Office Action; U.S. Appl. No. 11/435,502; dated Mar. 29, 2010, 11 pages.
Final Office Action; U.S. Appl. No. 11/528,225; dated Dec. 29, 2010, 12 pages.
Final Office Action; U.S. Appl. No. 11/558,046; dated Mar. 30, 2011, 17 pages.
Gage, “Current Progress in Cryosurgery,” Cryobiology 25, 483-486 (1988).
Hale et al., “Influence of chronic heat exposure and prolonged food deprivation on execretion of mahnesium, phosphorus, calcium, hydrogen ion & ketones,” Aerosp Med, 1968, pp. 919-26, vol. 39—issue (9).
Heller-Page et al., “Temperature-dependent skin disorders,” Journal of the American Academy of Dermatology, May 1988, vol. 18, No. 5, Pt 1, pp. 1003-1019.
Hemmingsson, “Attenuation in Human muscle and Fat Tissue in Vivo and in Vitro,” Acta Radiologica Diagnosis 23, 149-151 (1982).
Henry et al., “Les Dermatoses Hivernales,” Rev Med Liege, 1999, 54:11, 864-866. [Abstract Attached].
Holman, “Variation in cryolesion penetration due to probe size and tissue thermal conductivity,” Ann. Thorac. Surg. 53, 123-126 (1992).
Hong, “Patterns of Ice Formulation in Normal and Malignant Breast Tissue,” Cryobiology 31, 109-120 (1994).
International Search Report and Written Opinion for PCT/US2007/023492; Applicant: Zeltiq Aesthetics, Inc.; dated May 15, 2008, 7 pages.
International Search Report and Written Opinion for PCT/US2007/064016; Applicant: Juniper Medical, Inc.; dated Jul. 20, 2007, 13 pages.
International Search Report and Written Opinion for PCT/US2007/064017; Applicant: Juniper Medical, Inc.; dated Oct. 26, 2007, 16 pages.
International Search Report and Written Opinion for PCT/US2007/064018; Applicant: Juniper Medical, Inc.; dated Jul. 26, 2007, 13 pages.
International Search Report and Written Opinion for PCT/US2007/067638; Applicant: Juniper Medical, Inc.; dated Jan. 10, 2008, 11 pages.
International Search Report and Written Opinion for PCT/US2007/069694; Applicant: Juniper Medical, Inc.; dated Nov. 23, 2007, 12 pages.
International Search Report and Written Opinion for PCT/US2007/075935; Applicant: Zeltiq Aesthetics, Inc.; dated Apr. 10, 2008, 12 pages.
International Search Report and Written Opinion for PCT/US2007/083255; Applicant: Zeltiq Aesthetics, Inc.; dated Aug. 11, 2008, 8 pages.
International Search Report and Written Opinion for PCT/US2008/073930; Applicant: Zeltiq Aesthetics, Inc.; dated Nov. 7, 2008, 10 pages.
International Search Report and Written Opinion for PCT/US2007/062508; Applicant: Juniper Medical, Inc.; dated Jul. 20, 2007, 13 pages.
International Search Report and Written Opinion for PCT/US2009/058088; Applicant: Zeltiq Aesthetics, Inc.; dated Nov. 20, 2009, 14 pages.
International Search Report and Written Opinion for PCT/US2009/067973; Applicant: Zeltiq Aesthetics, Inc.; dated Feb. 18, 2010, 10 pages.
International Search Report for EP07758558.6; Applicant: Zeltiq Aesthetics, Inc.; dated Jul. 20, 2007, 4 pages.
International Search Report and Written Opinion for PCT/US2005/045988; Applicant: The General Hospital Corporation; dated Apr. 25, 2006, 14 pages.
International Search Report and Written Opinion for PCT/US2010/033290; Applicant: Zeltiq Aesthetics, Inc.; dated Feb. 25, 2011, 12 pages.
International Search Report and Written Opinion for PCT/US2011/022112; Applicant: Zeltiq Aesthetics, Inc.; dated Mar. 18, 2011, 11 pages.
International Search Report and Written Opinion for PCT/US2011/022444; Applicant: Zeltiq Aesthetics, Inc., dated Mar. 29, 2011, 14 pages.
Kellum, R.E. et al., “Sclerema Neonatorum: Report of Case and Analysis of Subcutaneous and Epidermal-Dermal Lipids by Chromatographic Methods,” Arch. Derm., 97:372-80, 1968.
Koska, J. et al., “Endocrine Regulation of Subcutaneous Fat Metabolism During Cold Exposure in Humans,” Ann N.Y. Acad, Sci., 967:500-05, 2002.
Kundu et al., “Breath acetone analyzer: diagnostic tool to monitor dietary fat loss,” Clin Chem, 1993, pp. 87-92, vol. 39, issue (1).
Kundu et al., “Novel solid-phase assay of ketone bodies in urine,” Clin Chem, 1991, pp. 15659, vol. 37—issue (9).
Kuroda et al., “Thermal distribution of radio-frequency inductive hyperthermia using an inductive aperture-type applicator: evaluation of the effect of tumour size and depth,” Med Biol Eng Comput, 1999, pp. 285-90, vol. 37—issue (3).
Laugier, et al., “In Vivo Results with a New Device for Ultrasonic Monitoring of Pig Skin Cryosurgery: The Echographic Cryprobe,” The society for Investigative Dermatology, Inc., vol. 111(2), Aug. 1998.
Levchenko, et al., “Effect of dehydration on lipid metabolism,” WMJ, 1978, pp. 95-7, vol. 50—issue (1).
Lidagoster, MD et al., “Comparison of Autologous Fat Transfer in Fresh, Refridgerated, and Frozen Specimens: An Animal Model Presented,” at the 16th Annual Meeting of the Northeastern Society of Plastic Surgeons: Burlington, VT, 1999, pp. 512-515.
Liu, A.Y.C. et al., “Transient Cold Shock Induces the Heat Shock Response upon Recovery at 37 C in Human Cells,” J. Biol. Chem., May 20, 1994, 269(20), 14768-14775.
Lvova, “Lipid levels and lipid peroxidation in frog tissues during hypothermia and hibernation,” WMJ, 1990, pp. 65-70, vol. 62—issue (1).
Maize, J.C., “Panniculitis,” Cutaneous Pathology, Chapter 13:327-344, 1998.
Malcolm, G. et al., “Fatty Acid Composition of Adipose Tissue in Humans: Differences between Subcutaneous Sites,” Am J Clin. Nutr., 50(2):288-91, 1989.
Merrill, Tom, “A Chill to the Heart: A System to Deliver Local Hypothermia Could One Day Improve the Lives of Heart-Attack Patients,” Mechanical Engineering Magazine, Oct. 2010 (10 pages).
Moschella, S.L. et al., “Diseases of the Subcutaneous Tissue,” Derm., Section 2:1169-1181, 1985.
Murphy, J.V. et al., “Frostbite: Pathogensis and Treatment,” The Journal of Trauma: Injury, Infection, and Critical Care, 48(1):171-178, 2000.
Nagao et al., “Dietary diacylglycerol suppresses accumulation of body fat compared to triacylglycerol in men a double-blind controlled trial,” J Nutr, 2000, pp. 792-7, vol. 130—issue (4).
Nagore et al., “Lipoatrophia semicircularis—a traumatic panniculitis: Report of seven cases and review of the literature,” Journal of the American Academy of Dermatology, Nov. 1998, 39:879-81.
Nielsen, “Thermoregulation in Rest and Exercise,” Acta Phys Scan Supp, 1969, pp. 6-74, vol. 323.
Nishikawa, “Ultrastructural Changes and Lipid Peroxidation in Rat Adipomusculocutaneous Flap Isotransplants after Normothermic Storage and Reperfusion,” Transplantation, 1992, 54, 795-801.
Non-Final Office Action; U.S. Appl. No. 10/391,221; dated Jul. 22, 2005, 6 pages.
Non-Final Office Action; U.S. Appl. No. 10/391,221; dated Jan. 25, 2006, 6 pages.
Non-Final Office Action; U.S. Appl. No. 10/391,221; dated May 30, 2007, 8 pages.
Non-Final Office Action; U.S. Appl. No. 11/016,196; dated Sep. 25, 2009, 8 pages.
Non-Final Office Action; U.S. Appl. No. 11/016,196; dated Apr. 22, 2008, 11 pages.
Non-Final Office Action; U.S. Appl. No. 11/359,092; dated Nov. 19, 2009, 13 pages.
Non-Final Office Action; U.S. Appl. No. 11/435,502; dated Jul. 17, 2009, 10 pages.
Non-Final Office Action; U.S. Appl. No. 11/528,225; dated Apr. 12, 2010, 11 pages.
Non-Final Office Action; U.S. Appl. No. 11/558,046; dated Jul. 12, 2010, 14 pages.
Non-Final Office Action; U.S. Appl. No. 11/741,271; dated Jul. 12, 2010, 9 pages.
Non-Final Office Action; U.S. Appl. No. 12/942,852; dated Jun. 30, 2011, 10 pages.
Non-Final Office Action; U.S. Appl. No. 11/528,225; dated Aug. 3, 2011, 13 pages.
Non-Final Office Action; U.S. Appl. No. 12/565,613; dated Sep. 23, 2011, 55 pages.
Pease, “An Integrated Probe for Magnetic Resonance Imaging Monitored Skin Cryosurgery,” Journal of Biomedical Engineering 117, 59-63, (1995).
Pech, “Attenuation values, volume changes and artifacts in tissue due to freezing,” Acta Radiologica 6, 779-782 (1987).
Peterson et al., “Bilateral Fat Necrosis of the Scrotum, Urology Service, Department of Surgery, Dermatology Service, Department of Medicine and Department of Pediatrics,” Letterman Army Medical Center, Journal of Urology, 1976, pp. 825-826, vol. 116, The Williams & Wilkins Co.
Phinney, S.D. et al., “Human Subcutaneous Adipose Tissue Shows Site-Specific Differences in Fatty Acid Composition,” Am J. Clin. Nutr., 60:725-29, 1994.
Rabi, “Metabolic adaptations in brown adipose tissue of the hamster in extreme ambient temperatures,” American Journal of Physiology 231, 153-160 (1976).
Renold, A.E., “Adipose Tissue,” Handbook of Physiology, Chapter 15:170-76, 1965.
Rubinsky, “Cryosurgery: advances in the application of low temperatures to medicine,” Int. J. Refrig. 190-199 (1991).
Schoning, et al., “Experimental Frostbite: Freezing Times, Rewarming Times, and Lowest Temperatures of Pig Skin Exposed to Chilled Air,” Cryobiology, 1990, pp. 189-193, 27.
Shephard, “Adaptation to Exercise in the Cold,” Sports Medicine, 1985, 2:59-71.
Wang et al., “Cryopreservation of cell/hydrogel constructs based on a new cell-assembling technique”, Sep. 5, 2009, 40 pages.
Wharton et al., “Cold acclimation and cryoprotectants in a freeze-tolerant Antarctic nematode, Panagrolaimus davidi,” Mar. 7, 2000, 2 pages.
Winkler et al., “Gene Transfer in Laboratory Fish: Model Organisms for the Analysis of Gene Function,” Transgenic Animals, 1997, pp. 387-395.
Young, H.E. et al., “Isolation of Embryonic Chick Myosatellite and Pluripotent Stem Cells,” J. Tiss. Cult. Meth., 14:85-92, 1992.
Aguilar et al., “Modeling Cryogenic Spray Temperature and Evaporation Rate Based on Single-Droplet Analysis”, Eighth International Conference on Liquid Atomization and Spray Systems, Pasadena, CA, USA, Jul. 2000, 7 pages.
Alster, Tina et el. “Cellulite treatment using a novel combination radiofrequency, infrared light, and mechanical tissue manipulation device,” J. of Cosmetic and Laser Therapy, vol. 7, 2005, p. 81-85.
Duck, Francis A., Physical Properties of Tissue, Academic Press Ltd., 1990, chapters 4 & 5, pp. 73-165.
Fournier, Luc et al. “Lattice model for the kinetics of rupture of fluid bilayer membranes,” Physical Review, vol. 67, 2003, 051908-1-051908-11.
Gabriel, S. et al., “The dielectric properties of biological tissue: II. Measurements in the frequency range 10 Hz to 20 GHz,” Phys. Medical Biology, vol. 41, 1996, p. 2251-2269.
Isambert, Herve “Understanding the Electroporation of Cells and Artificial Bilayer Membranes,” Phys. Review Letters, vol. 80, 1998, pp. 3404-3707.
Saleh, K.Y. et el. “Two-dimensional ultrasound phased array design for tissue ablation for treatment of benign hyperplasia,” Int. J. Hyperthermia, vol. 20, No. 1, Feb. 2004, p. 7-31.
Zouboulis et al., “Current Developments and Users of Cryosurgery in the Treatment of Keloids and Herpertrophic Scars”, Wound Repair and Regeneration, vol. 10, No. 2, pp. 98-102, 2002.
Ardevol, et al., “Cooling Rates of Tissue Samples During Freezing with Liquid Nitrogen”, Journal of Biochem and Biophysical Methods, 27, 1993, 77-86.
Peterson, et al., “Bilateral Fat Necrosis of the Scrotum”, 116 Journal of Urology, 1976, 825-826.
Schoning, et al., “Experimental Frostbite: Freezing Times, Rewarming Times, and Lowest Temperatures of Pig Skin Exposed to Chilled Air”, 27 Cryoboliogy, 1990, 189-193.
Hernan, P. et al., “Study for the evaluation of the efficacy of Lipocryolysis (EEEL)”, Nov. 30, 2011.
Hernan, R. P., “A Study to Evaluate the Action of Lipocryolysis”, 33(3) CryoLellers, 2012, pp. 176-180.
Jalian, H. R. et al., “Cryolipolysis: A Historical Perspective and Current Clinical Practice”, 32(1) Semin. Cutan. Med. Surg., 2013, pp. 31-34.
Zelickson, B. et al., “Cryolipolysis for Noninvasive Fat Cell Destruction: Initial Results from a Pig Model”, 35 Dermatol. Sug., 2009, pp. 1-9.
Related Publications (1)
Number Date Country
20120239123 A1 Sep 2012 US
Provisional Applications (1)
Number Date Country
61435944 Jan 2011 US